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ABSTRACT 
 
THERMOPHILIC FERRITIN: VERSATILE NANO HOST 
Katherine W. Pulsipher 
Ivan J. Dmochowski 
 
 Thermophilic ferritin from Archaeoglobus fulgidus (AfFtn) is a 24meric, hollow, 
cage-like protein, whose native function is the oxidation, mineralization, and storage of 
iron. Unique among ferritins, its self-assembly is dependent on high ionic strength, 
reflecting the deep sea thermal vent environment where A. fulgidus is found. This ionic 
strength dependence can be used to encapsulate charged cargo within the AfFtn cavity. Its 
subunits self-assemble into tetrahedral symmetry, resulting in four, large (4.5 nm), 
triangular pores, not found in other ferritins. Due to its size (12 nm outer diameter, 8 nm 
inner diameter), self-assembly properties, and potential for both genetic and chemical 
modification, AfFtn is an ideal nanocontainer for a variety of cargo, including inorganic 
nanoparticles and proteins.  
 We have sought to better understand the self-assembly of AfFtn and its 
encapsulation of various cargo. Guided by computational analysis and through 
mutagenesis, we have investigated the role of electrostatics along the AfFtn trimeric 
interface in self-assembly. We have developed a series of single point mutants with 
increasingly favorable cage assembly. One specific mutation, E65R, has a dramatic effect 
on AfFtn, almost entirely preventing disassembly and enhancing thermal stability by 14 
°C. By using a novel graphene-based microelectrode, we have determined that AfFtn 
	ix 
	
maintains its quaternary structure upon encapsulation of a gold nanoparticle, developing a 
new tool for investigating protein-nanomaterial interactions. We have also shown that 
AfFtn can be used to template seeded gold nanoparticle growth and have explored two 
often neglected factors in ferritin-nanoparticle templating: the charge of the gold salt used, 
and the size of the protein pores. Our results demonstrate that the open, porous structure of 
AfFtn allows more efficient particle growth than typical closed-pore ferritins. Finally, we 
have expanded the cargo uptake of AfFtn beyond nanoparticles to include proteins, 
encapsulating supercharged GFP. The AfFtn-cargo complexes developed here have 
application in catalysis, nanomaterials synthesis, and targeted delivery.  
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CHAPTER 1: INTRODUCTION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material in this chapter was originally published in the Israel Journal of Chemistry. It has 
been adapted here with permission from the publisher:  
Reprinted with permission from Pulsipher, K.W.; Dmochowski, I.J. Ferritin: Versatile 
Host, Nanoreactor, and Delivery Agent. Isr. J. Chem. 2016, 56, 660–670.  
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1.1 Protein Nanocontainers 
Biology is replete with small compartments, from whole cells to organelles, 
membrane vesicles, biomolecular complexes and active sites comprised of DNA, RNA or 
protein. Compartmentalization allows many chemical reactions necessary for life to occur 
simultaneously, without interference from other compounds. In addition to sequestering 
reagents for specific reactions, multi-subunit protein assemblies are capable of 
encapsulating useful cargo. The most well-studied examples of protein nanocontainers are 
viruses, which consist of a protein capsid shell and a nucleic acid cargo. Other examples 
include chaperone and heat shock proteins, which form hollow cages and play a role in 
protein folding. Ferritins are other natural compartments, whose hollow cavities can be 
filled with iron oxide (i.e., rust) and are responsible for helping maintain iron homeostasis. 
Natural protein nanocontainers can be re-purposed and filled with unnatural cargo 
for a variety of applications. Virus capsids have been shown to self-assemble around gold,1–
5 iron oxide,6 and semiconducting7 nanoparticles (NPs) of various sizes, replacing DNA or 
RNA. Different final capsid geometries can form depending on the size of the NP used.2 
Proteins themselves can also be encapsulated within a protein container. One example is 
the cage-like lumazine synthase from Aquifex aeolicus (AaLS). Directed evolution was 
used to generate an AaLS variant with a highly negatively charged cavity interior, capable 
of self- assembling around highly positively charged cargo.8 This mutant AaLS has been 
shown to encapsulate mutant superpositively charged GFP9,10 and other proteins with a 
deca-arginine tag,8,11 driven by electrostatic interactions. Functional enzymes can also be 
encapsulated such as carbonic anhydrase fused with a supercharged GFP analogue,12 a 
supercharged variant of ferritin,13 and a retro-aldolase fused with supercharged GFP.14   
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Ferritins, with outer diameter of 9-12 nm, are much smaller than viruses (D ≈ 30-
50 nm) and AaLS (D ≈ 30 nm). Because of their natural role to interface with inorganic 
materials, ferritins have found wide use encasing inorganic NP cargos. The NP can be 
generated in situ in the ferritin cage, or the protein can be disassembled and reassembled 
around a NP of appropriate size and shape. Ferritins have also served as nanocontainers for 
a variety of small molecules,15 including drugs16–18 and fluorescent dyes.19 Due to the 
relative ease of functionalizing proteins through genetic or chemical means, ferritin is an 
excellent delivery vehicle once a cargo is encapsulated. Their smaller size and lack of 
immunogenicity provide useful alternatives to virus capsids and AaLS.  
1.2 The Ferritin Family of Proteins 
Ferritins consist of multi-subunit, hollow, cage-like protein assemblies whose 
primary function is the oxidation and storage of iron. Ferric ion in water is scarcely soluble 
([Fe3+] = 10-18 M at pH 7), whereas iron oxide can be encapsulated within the ferritin shell 
at molar concentrations. The importance of ferritins is highlighted by their ubiquity; all 
living organisms save for a handful of archaea express some form of the protein.20 Ferritins 
can be split into two categories: 1) 24-subunit maxi-ferritins, found in prokaryotes and 
eukaryotes, and 2) 12-subunit mini-ferritins (DNA binding protein from starved cells, 
Dps), found only in prokaryotes. Maxi-ferritins can be further split into two groups: those 
that contain heme (found only in bacteria and known as bacterioferritins), and those that 
do not. Several examples of different ferritins are shown in Figure 1.1. Although sequence 
homology is low for most species of ferritin, their subunit structure is highly conserved: 
four α-helix bundles with an additional short fifth α-helix. Even without high sequence 
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homology, ferritin subunits of different species are sufficiently compatible to assemble and 
form heterocages similar to single-species cages.21 With an outer diameter of 
approximately 12 nm and an inner diameter of 8 nm, maxi-ferritins can hold up to ~4500 
Fe atoms.20,22,23 Ferritin with an iron core is known as holoferritin, while ferritin with its 
core removed is known as apoferritin. Mammalian ferritins, such as human ferritin (HuFtn) 
and horse spleen ferritin (HSF), have two different subunits called H (heavy) and L (light), 
owing to the different weights of their monomers (21 vs 19 kDa). The two different chains 
are compatible and can self-assemble to form a heterocage. HSF (or its apo form, HSAF) 
is one of the most widely used ferritins because it is commercially available and relatively 
inexpensive. It is comprised of mostly L ferritin.24 Pyrococcus furiosus ferritin (PfFtn) has 
received much attention due to its extremely high melting temperature,25 since its 
preliminary structural analysis26 in 2005 and complete crystal structure27 was published in 
2007. Most maxi-ferritins have a melting temperature of approximately 80 °C, while PfFtn 
has a Tm of over 120 °C. This makes it amenable for use in high-temperature reactions or 
experiments, which can be useful for preparing nanomaterials within the ferritin cavity. 
Mini-ferritins have 12 subunits,28,29 arranged in tetrahedral (32) symmetry with an 
outer diameter of 9 nm and inner diameter of 4.5 nm. While Dps can hold up to ~500 Fe 
atoms, it finds additional function in protecting organisms from oxidative damage.29 It is 
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overexpressed in cells under oxidative or nutritional stress and binds DNA non-specifically 
to protect it.30,31 
Figure 1.1. Representative examples of different types of ferritins. PDB codes (L to R): 2FHA, 
1BFR, 1SQ3, 1DPS. The first three on the left are maxi-ferritins, of eukaryotic, bacterial, and 
archaeal origin. The heme groups of bacterioferritin are shown in orange. Mini-ferritin Dps is on the 
far right. Inner and outer diameters are listed below each ferritin. A. fulgidus ferritin and Dps have 
tetrahedral symmetry, with one of the 3-fold axes shown. A. fulgidus also features uniquely large 
triangular pores, not yet observed in any other ferritin. Human H ferritin and bacterioferritin have 
octahedral symmetry, with one of the 4-fold axes shown. Reproduced with permission from Ref. 
32. 
1.3 Ferritin Self-Assembly 
Several studies have attempted to understand the ferritin self-assembly process 
from monomers into the 24mer cage. An early report using covalent crosslinking 
experiments suggested assembly intermediates of dimers (largest population), trimers, 
hexamers (smallest population), and dodecamers, with the assembly rate dependent on the 
protein concentration.32 The proposed mechanism is shown in Equation 1.1: 
24𝑚$ → 24𝑀$ ⇌ 8𝑀1 + 8𝑀2 ⇌ 8𝑀3 ⇌ 4𝑀6 ⇌ 2𝑀12 → 𝑀24        (1.1) 
 
where m1 and M1 denote the unfolded and folded monomers, respectively, and other 
subscripts denote the number of subunits per oligomer. Further studies using reversible 
dissociation with 2,3-dimethylmaleic anhydride showed that the trimer is less stable than 
the dimer in solution and that the hexamer rapidly forms the dodecamer.33  
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More recently, ferritin self-assembly has recently been probed using time-resolved 
small angle X-ray scattering (TR-SAXS).34 Starting with E. coli ferritin A at low pH, 
assembly was induced by raising the solution pH and monitored by TR-SAXS. The data 
were mostly consistent with the second-order assembly mechanism proposed above, with 
multiple intermediates including a large population of dimers, hexamers, and dodecamers, 
and a small population of tetramers. Rather than a sequential addition of individual subunits 
up to the assembled 24mer, individual subunits form dimers, which then form higher order 
oligomers that associate with each other (Figure 1.2). This mechanism avoids falling into 
a kinetic trap where assembly is started too many times and therefore not enough single 
subunits are available to complete the 24mers. Ferritin assembly thus differs from assembly 
of viral capsids, which follow a nucleation growth mechanism.35,36 
 
Figure 1.2. Ferritin self-assembly mechanism following association of oligomers. Reproduced with 
permission from Ref. 35. This is an unofficial adaptation of an article that appeared in an ACS 
publication. ACS has not endorsed the content of this adaptation or the context of its use. 
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Mutagenesis studies have explored what structural features are important for 
ferritin self-assembly. Orner et al. identified several “hot spot” residues in Dps and E. coli 
bacterioferritin whose mutation either shut down assembly entirely37,38 or stabilized it.39,40 
They accomplished this by modulating hydrophobic interactions, either by plugging water 
pockets with aromatic amino acids,39,40 by disrupting electrostatics along the dimer 
interface,38 or by replacing amino acids with alanine.37,41 In E. coli ferritin A, single point 
muations to alanine at the 3-fold axes decreased 24mer cage stability.42 Similarly, Theil et 
al. prevented assembly of bullfrog ferritin cages by inserting positively charged amino 
acids in the loop region of each subunit, leading to repulsion of like charges.43 More 
extensive modification involving cleavage of the last 23 amino acids in the monomer 
polypeptide chain enabled changes in the pH-dependent self-assembly of human H 
ferritin.44  
1.4 Ferritin Encapsulation Strategies 
Because of their size and robust self-assembly, ferritins are an excellent choice as 
a natural nano-sized container. The pores leading through the protein shell in most ferritins 
are quite small (<1 nm), so loading cargo within the apoprotein often requires disassembly 
and reassembly with the desired cargo in solution. Several methods for triggering self-
assembly are shown in Figure 1.3. Maxi-ferritin self-assembly is typically governed by 
pH.15,45 Certain species of Dps have also been reported with pH-sensitive assembly, 
including Listeria innocua46 and Mycobacterium smegmatis.47 While relatively simple, this 
assembly mechanism requires repeated transitions through the pI of ferritin, which can be 
damaging.45  
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Another assembly strategy involves a redesigned human ferritin that assembles 
only in the presence of copper ions.48 By altering the C2 interface between subunits to 
accommodate Cu(II) coordination, followed by destruction of native assembly stabilization 
contacts, Huard et al. formed a ferritin cage whose assembly is dependent on metal ions. 
Interestingly, the cage remained assembled, even after removal of copper, demonstrating 
the cooperative and stable nature of the protein quaternary structure. 
 
 
Figure 1.3. Methods for triggering ferritin self-assembly. From top to bottom (PDB): HuHFtn 
(2FHA), redesigned Cu-binding HuHFtn (4DYY), and AfFtn (1SQ3). Most mammalian ferritins, 
including HuHFtn shown, will disassemble and reassemble reversibly at acidic and mildly basic pH, 
respectively. HuHFtn was redesigned to only assemble in the presence of copper (blue spheres). 
The assembly was found to be irreversible, even when Cu2+ was removed. In AfFtn, assembly can 
be induced by increased ionic strength, and reversed by decreased ionic strength. Reproduced 
with permission from Ref. 32. 
 
One species of ferritin exhibits unique ionic strength-dependent self-assembly, in 
addition to pH-mediated assembly. Thermophilic ferritin from the hyperthermophilic 
archaeon Archaeoglobus fulgidus (AfFtn) disassembles in solutions of low ionic strength, 
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and reassembles in solutions of high ionic strength.49 This is presumably due to negatively 
charged residues residing at subunit interfaces, with electrostatic repulsion preventing 
assembly unless there are ions to screen the charges. Structurally, AfFtn is also unique 
because it has tetrahedral symmetry rather than the octahedral symmetry typical of other 
maxi-ferritins. Because of the tetrahedral arrangement of its subunits, there are four large 
(4.5 nm tip to opposite side) triangular pores in the 24mer cage, which have not been 
observed for other ferritins. Encapsulating a highly charged cargo, such as a gold 
nanoparticle (AuNP), can be done without adjusting the ionic strength of the solution.50–52 
This enables specific assembly induced by the cargo itself, leading to much higher 
encapsulation yields compared to other methods, which rely on serendipitously catching a 
cargo within the cavity. 
1.5 Properties of Gold Nanoparticles 
AuNPs are particles made of gold atoms with dimensions 1-100 nm. Although 
scientific interest in their preparation and properties has only been widespread within the 
last 50 years, AuNPs have been made for centuries, dating back to the Lycurgus cup in 4th 
century Rome,53 and in medieval times when AuCl3 salt was mixed with molten silica to 
form red cathedral stained glass windows. Michael Faraday was the first to scientifically 
investigate colloidal gold in the late 1800s,54 and his remarkably stable AuNP samples can 
be seen today in the Faraday Museum at the Royal Institution in London. Because of their 
high surface energy caused by dangling surface bonds, NPs are prone to aggregation. To 
stabilize NPs in aqueous solution, “ligands” are adsorbed to the surface. These can be bulky 
polymers which stabilize against aggregation by sterics, or charged small molecules, which 
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stabilize particles through electrostatic repulsion. When gold particles are on the nanoscale, 
their optical properties change dramatically, with size, shape, surface ligand and assembly 
state playing significant roles.55 Their optical properties can be attributed to surface 
plasmon resonance, the collective oscillation of electrons in the conduction band.55 The 
frequency of this oscillation is usually in the visible range, giving AuNPs their brilliant red 
to purple color. The enhanced electromagnetic field on the surface of the NPs can lead to 
enhancement of Raman signal or fluorescence of molecules adsorbed on the surface,56,57 
making AuNPs highly useful in sensing58 and imaging.59 AuNPs are also capable of 
converting energy from incident NIR light into heat, which can be applied in photothermal 
therapy.60 In addition to their many applications, AuNP synthesis is well-established and 
samples of high monodispersity can be made reproducibly. Thus, much of the work 
throughout this thesis will focus on AuNPs.  
1.6 The Protein-Nanoparticle Corona 
Because of their unique optical, magnetic, and chemical properties, NPs can be 
highly useful in medicine and biology, as improved imaging agents,61 diagnostic sensors,62 
and therapeutics.63 Multifunctional NPs create the possibility to combine therapeutic and 
diagnostic capabilities within the same “theranostic” particle. However, it is problematic 
that when NPs enter a complex biological fluid containing many proteins, such as serum, 
a protein “corona” forms at the NP surface.64,65 This is driven by the high surface energy 
of nanoparticles, with adsorption of proteins lowering their surface energy and helping to 
maintain a stable dispersion. Proteins that adsorb weakly to the surface show faster 
exchange kinetics, called a “soft” corona, while proteins with higher affinity bind more 
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tightly with slower exchange times, forming a “hard” corona. Thus, when an inorganic NP 
is introduced into a biological medium, its core material and surface ligands are typically 
masked by the adsorbed proteins on the surface. This is an extremely important 
consideration when designing NPs for biological applications. As the NP passes through 
different organs or tissues, different proteins will be adsorbed/desorbed, manifesting the 
history of the NP in the proteins presented on its surface. This corona can change how the 
NP interacts with cells and may change where it localizes.66 Understanding how proteins 
and NPs interact is therefore of vital importance so that NPs can be used for their intended 
purpose upon introduction into a biological system.  
Adsorption to a NP surface can induce conformational changes in a protein. For 
example, polystyrene NPs induced decreases in α-helicity in apolipoprotein, human serum 
albumin, and lysozyme,67 while denatured lysozyme, chymotrypsin, and papain were all 
refolded after adsorption on a AuNP surface.68 Protein unfolding on NP surfaces can have 
significant consequences. When incubated with 90-nm AuNPs, lysozyme unfolded upon 
adsorption and induced NP aggregation.69 In the presence of AuNPs capped with 
poly(acrylic acid), fibrinogen has been shown to unfold, displaying a normally buried 
binding epitope.70 This enabled the interaction of fibrinogen with the integrin receptor 
Mac-1, which promotes an inflammatory response. When comparing 5-, 10-, and 20-nm 
particles, fibrinogen on 20-nm AuNPs did not interact with Mac-1, highlighting the 
importance of NP size. Trypsin was shown to unfold upon binding to polystyrene and silica 
NPs, causing a major loss of enzyme activity.71 Proteins have also been shown to help 
stabilize NP dispersions.72,73 Multiple factors including NP size/surface curvature,74 
surface ligands/charge,75 and shape/crystal facet76,77 can affect its interactions with 
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proteins. In general, highly charged NPs tend to adsorb proteins more strongly, while 
neutral NPs, especially those capped with high-molecular weight polyethylene glycol 
(PEG), minimize protein corona formation.78–80 Improved understanding and control over 
how NPs and proteins interact will enable their more effective use in biological 
applications.  
1.7 Ferritin-Nanoparticle Interactions 
Through ferritin disassembly and reassembly, NPs (ligand shell included) smaller 
than the interior diameter of ferritin can be encapsulated. This is generally done using pH 
control over the assembly process. One example is the encapsulation of CeO2 NPs within 
pig spleen ferritin.81 The resulting ferritin-CeO2 “nano-truffle” exhibited significant 
antioxidant activity, due to electron shuttling between Ce(III) and Ce(IV). The activity of 
the ferritin-CeO2 was higher than CeO2 NPs alone, due to charge transfer between ferritin 
and the NP. pH disassembly/reassembly was also used to encapsulate hybrid melanin/iron 
NPs within HSAF for magnetic resonance and photoacoustic imaging applications.82  
 In contrast to the pH-dependent disassembly, AfFtn has been shown to disassemble 
in low-salt conditions and reassemble around pre-formed AuNPs, without increasing the 
solution ionic strength.50–52 A thermocycling method (50 cycles of 4 to 50 °C) was used 
initially to encapsulate 10-nm AuNPs capped with citrate, glutathione, bis(p-
sulfonatophenyl(phenylphosphine)) (BSPP), or 4-dimethylaminopyridine.50 Encapsulation 
was found to be nearly quantitative as confirmed by transmission electron microscopy 
(TEM), regardless of surface ligand. However, the α-helicity of the protein was 
significantly decreased after the encapsulation process. The thermal unfolding of AfFtn is 
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not reversible, so it is unsurprising that the repeated extreme changes in temperature led to 
partial denaturation.  
Shown in Figure 1.4, a gentler encapsulation method was presented by Cheung-
Lau et al.51 5-nm AuNPs coated with BSPP were encapsulated after 48 h with gentle 
agitation at room temperature. The resulting AfFtn-NP conjugates maintained the 
secondary structure, stoichiometry, thermal stability, and overall diameter of the native 
protein. This suggests a soft, non-perturbative interaction between the protein and NP, 
which is very different from the hard corona discussed above. The AfFtn-NPs were more 
stable to salt precipitation compared to “bare” particles. The assembly was found to be 
reversible; upon addition of excess salt, the NPs could be precipitated, recovering AfFtn 
with full ferroxidase activity. The lack of significant protein denaturation is notable and 
opens the AfFtn-NP conjugate to further use. Because spherical NP surfaces are relatively 
isotropic, it is difficult to functionalize them with spatial or stoichiometric specificity. 
Having AfFtn self-assembled in its native state around an NP gives a specific number of 
amino acid side-chain functional groups in precisely defined locations. This could be useful 
in attaching antibodies or other targeting ligands, where control over the number and/or 
spacing of ligands is important. As the primary interaction between the NP and AfFtn is 
with the surface ligands, this encapsulation method should be generalizable to NPs of any 
composition, so long as a suitable ligand is chosen. 
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Figure 1.4. AuNP encapsulation by AfFtn. Decreasing the ionic strength of the solution causes 
cage disassembly. Addition of AuNPs of comparable size to the AfFtn interior diameter induces 
protein reassembly, with a stable conjugate formed by 48 h at room temperature with gentle 
rocking. The process is reversible, with addition of excess salt precipitating the NPs and leaving 
native protein in solution. Reproduced with permission from Ref. 52. 
1.8 Targeted Ferritin Delivery  
Encapsulating cargo within ferritin is useful for fundamental understanding of 
protein-nanoparticle interactions. However, to move beyond basic science and into 
biomedical applications, delivery of the ferritin-cargo conjugate is necessary. Delivery of 
therapeutics directly to where they are needed in the body will greatly improve drug 
efficacy, lower dosages, and decrease side effects, especially for toxic treatments such as 
chemotherapy in cancer. It can be challenging to append targeting moieties (folate, 
peptides, antibodies, etc.) to small molecule drugs or biologics without altering their 
activity. Rather than directly tagging the drug itself, drugs can be placed within a tagged 
carrier to direct them to a specific site. With its biocompatibility and ease of 
functionalization, ferritin is an excellent delivery vehicle in the oft-neglected 10-20 nm 
particle size range.  
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Different ferritins have intrinsic targeting capabilities due to their uptake by specific 
receptors. Human H ferritin binds transferrin receptor 1 (TfR1) and can be internalized into 
cells through this pathway,83 while human L ferritin is taken up by the Scara5 receptor.84 
Uptake of HSAF in human intestinal cells was also shown to be receptor-mediated.85 
Delivery of neural drugs carbachol and atropine to treat pancreatic cancer in mice was 
achieved using human H ferritin.86 Gefitinib (an epidermal growth factor receptor tyrosine 
kinase inhibitor) was also delivered this way,16 as was methylene blue, a photosensitizer.18 
Inorganic nanoparticles have also been delivered through the natural targeting of ferritin. 
Pt NPs encapsulated within were specifically delivered to human intestinal Caco-2 cells 
for the purpose of decreasing oxidative stress.87 Cells treated with the ferritin-NPs had 
significantly increased viability compared to controls when challenged with 5 mM H2O2. 
It is also possible to redirect ferritin localization through conjugation of antibodies88 
or other targeting groups, such as peptides, to the ferritin surface.89–92 Ferritin conjugated 
with RGD4C peptide enabled the delivery of doxorubicin to an U87MG subcutaneous 
tumor model, resulting in a longer circulation half-life, higher tumor uptake and tumor 
growth inhibition, and less cardiotoxicity than the free drug.93 Genetic modification with 
an α-melanocyte-stimulating hormone peptide enabled ferritin targeting of melanoma 
cells.94 Cobalt-doped magnetite NPs were encapsulated within the targeted ferritin for 
hyperthermia treatment. Melanoma cells exposed to the ferritin-Co/magnetite NP 
conjugates showed a 50% decrease in cell viability after treatment with an alternating 
magnetic field, while control cells remained alive. 
We have recently explored targeting ferritin to the endothelium,88 the single-cell 
layer lining the interior of blood and lymphatic vessels. Dysfunction in the endothelium is 
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linked to a number of diseases including hypertension, heart failure, diabetes, kidney 
failure, and atherosclerosis.95 Problems with the pulmonary endothelium in particular are 
associated with acute respiratory distress syndrome, pulmonary hypertension, pulmonary 
embolism, and graft dysfunction after lung transplantation,96 and targeting the pulmonary 
endothelium remains a challenge. The most commonly used clinical method for delivery 
to the lungs is inhalation, which is not always effective for therapeutics and may be 
especially problematic if lung activity is impaired. Recently developed strategies for 
pulmonary endothelium targeting include rod shaped polymeric particles,97 spherical 
polymeric particles,98 and liposomes,99 all of which have dimensions larger than 100 nm. 
Delivery vehicle size can have a large effect on targeting efficiency, and less work has been 
done exploring pulmonary endothelium delivery with smaller particles. Ferritin provides a 
monodisperse, biocompatible sample with significantly smaller diameter compared to 
conventional delivery agents, along with relative ease of chemical or genetic modification.  
 To target the pulmonary endothelium, HSAF was chemically tagged with different 
targeting antibodies including anti-platelet cell adhesion molecule-1 (anti-PECAM-1) and 
anti-intercellular adhesion molecule-1 (anti-ICAM-1) through maleimide-sulfhydryl 
coupling. Maleimides were introduced in HSAF by use of lysine-reactive succinimidyl 4-
(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), and sulfhydryls were 
introduced in the antibodies using N-succinimidyl S-acetylthioacetate (SATA). 
Conjugation with single chain antibody fragments and whole antibodies was compared. As 
expected, fewer whole antibodies were attached to the ferritin surface, presumably due to 
greater steric hindrance compared to the fragments. The antibody-HSAF conjugates were 
found to bind specifically to cells expressing either ICAM-1 or PECAM-1, corresponding 
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to the particular antibody labeling. By conjugating HSAF with IgG, the natural TfR1 
uptake pathway could be avoided, compared with unconjugated HSAF, demonstrating re-
direction of ferritin’s native targeting. Biodistribution studies in mice showed that the 
antibody-targeted ferritins localized predominantly in the lungs, at percentages equal to or 
higher than other commonly used polymeric NPs or liposomes (Figure 1.5). These larger 
delivery agents have considerably more antibodies on their surface compared to HSAF, 
which makes this finding all the more surprising. We suspect that the comparable targeting 
efficiency of HSAF is due to how the antibodies are presented on the surface, making it 
easier to bind their targets, compared with polymeric NPs and liposomes. Current work is 
ongoing in our lab to load ferritin with therapeutic molecules and demonstrate their 
delivery in vivo and in vitro.  
 
Figure 1.5. Antibody-ferritin conjugate (Ab/FNP) targeting pulmonary endothelium. Compared with 
free antibody (Ab) or antibody-polymeric NP (Ab/NP), Ab/FNP has greater or comparable targeting 
capability to either intercellular adhesion molecule (ICAM) or platelet endothelial cell adhesion 
molecule (PECAM). Reprinted with permission from Ref. 89. Copyright 2015 American Chemical 
Society. 
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 The work presented in this thesis highlights the versatility of AfFtn in exploring its 
encapsulation capabilities. In Chapter 2, we report designed AfFtn mutants with altered 
assembly properties and how these changes affect their interactions with AuNPs. In 
Chapter 3, we demonstrate using both novel and conventional methods that AfFtn 
maintains its quaternary structure upon AuNP encapsulation, describing a new analytical 
technique for understanding protein-NP interactions. In Chapter 4 we explore AuNP 
seeded growth templating by AfFtn and the effect of the gold salt used, as well as the AfFtn 
pore size. In Chapter 5 we broaden AfFtn encapsulation beyond inorganic nanoparticles to 
proteins, using supercharged GFP(+36) as a proof-of-concept. In the Appendix we show 
preliminary data of AfFtn encapsulating quantum dots (QDs) and its effect on QD optical 
properties. From nanomaterials synthesis to therapeutic protein encapsulation, AfFtn is a 
highly useful nanocontainer with great potential.  
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CHAPTER 2: THERMOPHILIC FERRITIN 24MER ASSEMBLY AND 
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The content of this chapter has been submitted for publication. It has been adapted here:  
Reprinted with permission from Pulsipher, K.W.; Villegas, J.A.; Roose, B.W.; Hicks, 
T.L.; Yoon, J.; Saven, J.G.; Dmochowski, I.J. Thermophilic Ferritin 24mer Assembly and 
Nanoparticle Encapsulation Modulated by Interdimer Electrostatic Repulsion. 2017. 
Submitted. 
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2.1 Introduction 
Protein cages are large, multi-subunit structures with hollow interiors. Because of 
their size and unique structural properties, these cages are useful in many applications 
including bio-targeting,88,100 drug delivery,92,101 catalysis,102,103 and nanoelectronics.104 
Ferritins make up a ubiquitous family of protein cages, important for iron storage in most 
organisms. Maxi-ferritins share a similar overall structure: 24 tetrahelical subunits, 
assembled to form a hollow, roughly spherical shape. Eukaryotic ferritins remain stably 
assembled as 24mers over a wide pH range.105 Some prokaryotic ferritins exist as mixture 
of fully assembled 24mer and disassembled dimer.106 The dimer is a common intermediate 
in ferritin self-assembly, and the 24mer/dimer distribution can be altered by single point 
mutations. Orner et al. identified several “hot spot” residues in E. coli bacterioferritin and 
ferritin-like DNA binding protein from starved cells (DPS) whose mutation either shut 
down assembly entirely37,38 or stabilized it.39,40 They accomplished this by modulating 
hydrophobic interactions, either by plugging water pockets with aromatic amino acids,39,40 
by disrupting electrostatics along the dimer interface,38 or by replacing amino acids with 
alanine.37,41 In E. coli ferritin A, single point mutations to alanine at the 3-fold axes 
decreased 24mer cage stability.42 Similarly, Theil et al. prevented assembly of bullfrog 
ferritin cages by inserting positively charged amino acids in the loop region of each subunit, 
leading to repulsion of like charges.43 More extensive modification involving cleavage of 
the last 23 amino acids in the monomer polypeptide chain enabled changes in the pH-
dependent self-assembly of human H ferritin.44 Human H ferritin was also redesigned to 
self-assemble only in the presence of copper ions.48 
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Figure 2.1. Salt-dependent assembly for wild type AfFtn. Under high-salt conditions (800 mM 
NaCl), the 24mer cage predominates. Under low-salt conditions (<200 mM NaCl), the protein 
disassembles into twelve dimers. The dimer is highlighted in blue in the 24mer cage on the left. 
Inset shows close up of mutation positions at the trimeric interface. The crystallographic structure 
of AfFtn (PDB ID: 1SQ3) was used to generate the figure.49 
 In this chapter, we investigate the self-assembly of thermophilic ferritin from the 
archaeon Archaeoglobus fulgidus (AfFtn), which has unique salt-dependent assembly, not-
yet-found in other ferritins. Shown in Figure 2.1, at high ionic strength (800 mM NaCl), 
the 24mer is the dominant assembly state. At lower ionic strength (<200 mM NaCl), the 
protein disassembles into stable dimers, which we refer to herein as the protein subunits.49,50 
We have used the ionic strength-dependent self-assembly of AfFtn to encapsulate citrate- 
or BSPP-functionalized gold nanoparticles (AuNPs), rendering them more biocompatible 
and stable to salt-induced precipitation.50–52 The encapsulation process happens under mild 
conditions, at room temperature with gentle agitation. The resulting AfFtn-AuNP assembly 
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maintains native protein secondary structure, subunit stoichiometry, melting temperature, 
and ferroxidase activity, thus highlighting unusual protein-AuNP complementarity.  
The crystal structure of AfFtn (PDB ID: 1S3Q)49 contains a trimeric interface rich 
in negatively charged residues. We hypothesized that electrostatic repulsion at this 
interface prevents subunit assembly at low ionic strength and neutral pH, given that the 
estimated pI of AfFtn is 4.7. Subunit-subunit electrostatic repulsion was found to be 
important in governing the rate of self-assembly of E. coli ferritin A, which typically exists 
only as a 24mer except in acidic conditions.107 As other ferritins do not feature salt-
mediated self-assembly, AfFtn provides a unique opportunity to investigate the role of 
subunit interface electrostatics in protein cage formation.  
 We hypothesized that decreasing electrostatic repulsion between anionic subunits 
by designed amino acid substitution should promote 24mer formation at low-salt 
concentrations. We tested this hypothesis by introducing positively charged groups at 
various positions along the dimer-dimer interface. As we have employed previously in the 
redesign of ferritin proteins,108,109 a statistical computational design strategy was used to 
calculate theoretical amino acid probabilities at selected sites. The resulting probabilities 
were used to guide the selection of point mutations likely to be compatible with the overall 
protein structure as well as the supramolecular assembly. Three single-point mutants 
(shown in Figures 2.1 and 2.2) were experimentally characterized, where each mutation 
substituted a single negatively charged or neutral residue for a positively charged one. We 
investigated the thermal stability of the mutants and explored changes in the self-assembly 
equilibrium, kinetics, and reversibility at different salt concentrations. Finally, we tested 
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the capability of each mutant to encapsulate and stabilize AuNPs, as well as template 
further AuNP growth. We conclude that altering electrostatic interactions between ferritin 
subunits provides a versatile approach to modulating protein cage assembly.  
 
Figure 2.2. Computationally designed mutations along the trimeric interface. Wild-type residues 
(dark blue border): (a) E65, (b) A127, and (c) D138. Single-point mutations: (d) A127R (violet 
border), (e) D138K (teal border), and (f) E65R (orange border). Different protomers (chains) are 
rendered distinct colors: cyan, yellow and pink. 
2.2 Results 
 
Computational Design of AfFtn Mutants  
In the design calculations, we sought to identify mutations that both introduce a 
positively charged residue and span the interface between adjacent protamers. We focused 
on the probabilities of amino acid type (a) at each site i, Pi(a), or the ratio relative to the 
wild-type residue Pi(a) / Pi(awt). At site 34, the wild-type Asp was the most probable 
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residue, and as a result, this site was not selected for mutation. At site 65, Arg was the most 
probable amino acid (P65(R) = 0.83), yielding the suggested mutation E65R. At site 127, 
Arg was the most probable amino acid (P127(R) = 0.63), and the mutation A127R was 
selected. At site 131, Lys was the most probable amino acid P131(K) = 0.93. Upon 
examining the resulting model structures, the conformations of this side chain directed the 
ammonium group within the protomer, and the side-chain interactions did not span an 
interface with other protomers; this site was not selected for mutation. At site 138, the four 
most probable amino acids were Arg, Asn, Asp, and Lys, and P138(K)/ P138(D) = 1.49.  The 
mutation D138K was selected at this site.  
General Protein Characterization  
We prepared E65R, A127R, and D138K single point mutants using standard site-
directed mutagenesis. After expression and purification, protein purity was verified by 
SDS-PAGE and UV-vis spectroscopy (Figures 2.3 and 2.4) and identity was verified by 
MALDI-TOF MS (Figure 2.5).  
 
Figure 2.3. SDS-PAGE denaturing gels showing >90% purity for all proteins used and a monomer 
MW of approximately 20 kDa, as expected.  
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Figure 2.4. Normalized UV-vis spectra of purified proteins. No significant DNA contamination is 
observed.  
 
Figure 2.5. MALDI-TOF-MS for all proteins used. Measured mass for monomer (expected): wt 
20315.3 (20316.1 Da), A127R 20411.5 (20401.2 Da), D138K 20329.3 (20329.2 Da), E65R 20347.8 
(20343.1 Da). Peaks at ~40 kDa correspond to dimer. Sinapinic acid was used as a matrix, and 
linear-positive mode was used as the method.  
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We then verified cage formation in 800 mM NaCl by transmission electron 
microscopy (TEM). Shown in Figure 2.6 and summarized in Table 2.1, cages with 
approximately the same diameter as wild type (wt) were observed in TEM micrographs, 
showing the mutations did not inhibit self-assembly in high ionic strength solution. 
Dynamic light scattering (DLS) also showed similar results, with all mutants having 
average particle diameters within 2 nm of that of wt (Davg(wt) = 13.5 nm). Circular 
dichroism (CD) spectra for all three mutants showed almost no change compared to wt, 
demonstrating a lack of perturbation in secondary structure (see Figure 2.7). This is 
unsurprising, as ferritins and ferritin-like proteins have been shown to be stable to extensive 
mutagenesis.109 
 
 
Figure 2.6. TEM micrographs and size distributions for wt and mutant AfFtn. Similar cage 
structures were observed for all samples, indicating mutations did not prevent self-assembly. Grids 
were stained with either 2% uranyl acetate or 2% ammonium molybdate negative stain. Particle 
size was measured manually using ImageJ.110 Scale bars are 100 nm.  
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Table 2.1. Assembled cage characterization in 800 mM NaCl. 
Sample Davg TEM (nm)a Nb Davg DLS (nm) [PDI] Tm (°C) c 
wt 13.2 ± 1.1 101 13.5 [0.035] 84 
A127R 13.3 ± 0.9 117 13.6 [0.052] 85 
D138K 12.3 ± 1.3 110 14.9 [0.103] 84 
E65R 11.1 ± 0.9 173 12.9 [0.059] 98 
aDavg is average diameter. 
bN is number of particles that were measured manually using ImageJ111 to calculate average diameter. 
cTm was measured by CD for wt, A127R, D138K and by DSC for E65R.  
 
 
Figure 2.7. CD spectroscopy for wt and mutant AfFtn. Minimal changes in secondary structure are 
seen upon mutation. Sample concentration was 0.3 mg/mL in 800 mM NaCl, 20 mM phos, pH 7.6 
buffer.  
 Next, we investigated the thermal stability of the mutants using CD spectroscopy 
(Figure 2.8a). Because CD spectroscopy monitors changes in secondary structure, our 
thermal stability data only provide information on the secondary structures of individual 
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four-helix bundle subunits. At 0.3 mg/mL, both A127R and D138K showed nearly 
identical thermal stability to wt AfFtn (Tm = 84 °C, Table 1). However, E65R did not unfold 
for T < 96 °C, and we were unable to measure its Tm by CD. Instead, we turned to 
differential scanning calorimetry (DSC), which uses a pressurized, sealed sample chamber, 
enabling us to measure higher melting temperatures in aqueous conditions. By DSC at 0.5 
mg/mL, we measured a Tm = 98 °C for E65R; using the same technique, we measured Tm 
= 84 °C for wt, which confirmed the CD-determined values (Figure 2.8b). Remarkably, 
E65R has thermal stability enhanced by 14 °C compared to the hyperthermophilic wt 
protein and other two mutants.  
 
Figure 2.8. Thermal stability characterization of AfFtn mutants. a) CD spectroscopy was used to 
generate fraction folded plots for A127R and D138K. b) Differential scanning calorimetry traces for 
wt and E65R.  
 Shown in Figure 2.9, we also investigated the enzymatic activity of the mutants 
using an absorbance-based ferroxidase assay.112 An aliquot with 480 eq of Fe2+ was added 
to each sample and oxidation to Fe3+ was monitored by the increase in iron mineral 
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absorbance at 315 nm. E65R had slightly enhanced activity compared to wt, while D138K 
had slightly diminished activity and A127R had significantly diminished activity. A127R 
is closest to the ferroxidase site of the protein and likely interacts with glutamates in 
positions 128 and 131, potentially perturbing their activity. In light of minimally affected 
structural features and thermal stability mentioned above, this represents a localized 
disruption of the ferroxidase site compared to wt AfFtn. 
 
Figure 2.9. Ferroxidase activity of wt and mutant proteins. D138K and E65R show similar activity 
to wt, while A127R shows inhibited ferroxidase, indicating some perturbation to the ferroxidase site 
of the protein.  
 
Self-assembly Equilibria  
After general characterization of all mutants, we were interested in how 
mutagenesis affected the dimer-24mer equilibrium. To investigate the assembly state of 
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the proteins at varying salt concentrations, we used size exclusion chromatography (SEC), 
tryptophan fluorescence, DLS, and native gel electrophoresis.  
 
Figure 2.10. Size exclusion chromatography quantification of the amount of 24mer present at 
various salt concentrations for all proteins. Compared to wt (dark blue) at low salt concentrations, 
D138K has a slightly larger percentage of the fully formed assembly (orange), and A127R has a 
slightly larger percentage of the dimer (teal). E65R has greater than 90% assembly at all salt 
concentrations tested, [NaCl] = 0-800 mM (violet).  
 
SEC was performed after incubating each mutant overnight at 5 mg/mL in solutions 
of different salt concentrations, as seen in Figure 2.10. The peak in the SEC trace at ~10 
mL was attributed to 24mer, while the peak at ~14 mL was attributed to dimer (see Figure 
2.11), based on column MW calibration.  
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Figure 2.11. Representative size exclusion traces showing 24mer elution at ~10 mL and dimer 
elution at ~14 mL.  
The area under the peaks was used to quantify the percentage 24mer for each 
protein at each salt concentration. As expected, at high-salt conditions ([NaCl] > 500 mM), 
all proteins showed nearly 100% 24mer. At lower salt conditions ([NaCl] < 200 mM), 
different behaviors were observed. A127R is slightly less likely to self-assemble in low-
salt conditions compared to wt, while D138K has slightly higher propensity to assemble, 
with higher 24mer populations than wt at 0, 20, and 100 mM NaCl. E65R shows >90% 
24mer under all salt conditions tested, demonstrating a dramatic change in self-assembly 
equilibrium.  
  To corroborate SEC results, we used Trp fluorescence, which is reflective of the 
solvation environment of Trp residues in the protein (Figure 2.12a). AfFtn contains four 
Trp residues per single-chain subunit, two of which are predicted to see some change in 
solvation upon disassembly (Trp44 and Trp124). For wt, in 800 mM NaCl buffer where 
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AfFtn is completely assembled, the Trp emission maximum is at 332 nm. In 0 mM NaCl 
buffer, where AfFtn is disassembled into dimers, the emission red shifts to 337 nm, 
consistent with the Trp residues becoming more solvent exposed. We measured the Trp 
fluorescence spectrum for each protein in 0 and 800 mM NaCl buffer. All of the mutants 
exhibited similar fluorescence spectra to wt at 800 mM NaCl, with similar peak shapes and 
maximum emission wavelengths. E65R showed a slight blue shift compared to wt, with an 
emission maximum of 331 nm compared to 332 nm for wt. At 0 mM NaCl, significant 
changes were observed. A127R and wt had the largest red shifts, moving to 337 and 338 
nm, respectively, indicating disassembly for both proteins. D138K had a red shift of only 
2 nm, while E65R only shifted by 1 nm. These trends for D138K and E65R match those 
observed by SEC, with E65R showing minimal structural changes with changing salt 
concentration, and D138K showing smaller changes than wt.  
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Figure 2.12. Additional size characterization of AfFtn mutants. a) Tryptophan fluorescence results 
for wt and mutants. b) Dynamic light scattering results. All proteins in 800 mM NaCl show complete 
24mer assembly. At 0 mM NaCl, only E65R remains assembled, while D138K forms discrete 
dimers and some aggregate, and wt and A127R predominantly form aggregates of dimers.  
 
 DLS corroborated Trp fluorescence results showing A127R with similar self-
assembly behavior to wt, E65R, and D138K, with increased 24mer population at low-salt 
conditions (Figure 2.12b). Like wt, A127R 24mer was present at 800 mM NaCl and not at 
0 mM NaCl. DLS also indicated that at 5 mg/mL protein and 0 mM NaCl, A127R, wt, and 
D138K (to a smaller extent) form a broad range of higher molecular weight aggregates. 
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These aggregates are too weakly associated to withstand FPLC treatment as no aggregates 
were observed on the sizing column under any conditions. Aggregate formation is 
concentration-dependent, as wt samples at 1 mg/mL had individual dimer visible in DLS 
data, but at 5 mg/mL only aggregate was present (Figure 2.13). D138K was predominantly 
24mer at 800 mM NaCl and mostly dimer (with some 24mer) at 0 mM NaCl, whereas 
E65R remained fully assembled at both salt concentrations. Native gel results also support 
the uniqueness of the E65R mutant, as shown in Figure 2.14, where E65R was the only 
protein to run similar to horse spleen apoferritin (HSAF, used as a control due to its lack 
of salt-mediated disassembly). WT, D138K, and A127R all ran as smaller species.  
 
Figure 2.13. DLS in no-salt conditions at varying protein concentrations. At higher concentrations, 
wt and A127R have a greater tendency to aggregate compared to D138K, which maintains discrete 
dimers at all protein concentrations tested.  
 
	35 
	
 
Figure 2.14. Native gel (4-20%) showing enhanced stability of E65R 24mer compared to wt, 
A127R, and D138K. Horse spleen apoferritin (HSAF) was used as a marker to indicate where a 
ferritin 24mer cage should run, as it does not have ionic strength-dependent assembly.  
Self-assembly Kinetics  
By monitoring particle size using DLS, we were also able to investigate differences 
in the kinetics of 24mer assembly for wt, A127R, and D138K. Because E65R does not 
disassemble with decreasing ionic strength, no changes were observed by DLS or SEC 
upon changing the buffer conditions. We started with disassembled protein in 0 mM NaCl 
buffer, which was transferred to 800 mM NaCl buffer to induce self-assembly. The rate of 
assembly was concentration-dependent, particularly for A127R and wt (Figure 2.15). For 
wt protein at 5 mg/mL, assembly appeared to be complete within 4 h. For A127R at 5 
mg/mL, assembled 24mer population increased up to 75% over 4 h, and then stalled with 
no further assembly. At 2 mg/mL, both wt and A127R took approximately 24 h to 
reassemble. At 1 mg/mL, wt assembly occurred within 10 min (the time it took to prepare 
samples and take the DLS measurement), and A127R was >90% 24mer within 2 h. 
Assembly was significantly faster for D138K compared to wt and A127R at 2 and 5 
mg/mL. At these concentrations the D138K samples were >90% 24mer within 10 min. At 
	36 
	
1 mg/mL, assembly was still quite fast, with a population of >80% 24mer within 10 min. 
Rapid assembly kinetics with D138K at all concentrations tested is consistent with lack of 
aggregate formation, and an orderly process of subunit assembly. This feature should lead 
to more reversible and higher-yielding ferritin disassembly and assembly processes with 
D138K, e.g., as required for cargo loading. 
 
 
Figure 2.15. DLS was used to monitor assembly of wt and mutants, starting from dimers. Assembly 
rate was concentration-dependent for A127R, with faster assembly at lower protein concentrations. 
WT showed fastest assembly at 1 mg/mL, followed by 5 mg/mL and 2 mg/mL. D138K assembled 
within the time it took to take the measurement for all protein concentrations tested.  
 
We observed a less dramatic difference among the protein disassembly kinetics, 
moving samples from 800 mM NaCl to 0 mM NaCl. By DLS, A127R and wt appeared to 
disassemble immediately, producing large aggregates. The disassembly of D138K was 
more difficult to monitor by DLS due to the relative similarity in diameter of 24mer and 
dimer (and lack of aggregates). By SEC, as shown in Figure 2.16, we could observe 
disassembly for all three proteins within 25 min (the measurement time). Some 24mer 
remained for D138K within this time frame, which matched the results for the 0 mM NaCl 
equilibrium measurement (Figure 2.10).  
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Figure 2.16. SEC shows fast disassembly for all three proteins. Superdex200 Increase column 
equilibrated with 0 mM NaCl buffer with a flow rate of 0.9 mL/min was used. Samples were 2 mg/mL 
and were buffer exchanged using a Zebaspin column immediately before chromatography.  
X-ray Crystallography  
To better understand the significantly enhanced stability of E65R, we obtained a 
3.08 Å resolution X-ray crystal structure (PDB ID 5V5K). Although the quality of the 
electron density maps does not allow for sidechain conformations to be confidently 
modeled, the crystallography data do offer insights pertaining to the global structure of the 
E65R mutant. As shown in Figure 2.17, the structure of 24mer E65R shows a shift in the 
symmetry of the assembled cage to octahedral (as opposed to the tetrahedral structure of 
wt), resulting in a lack of the large triangular pores. The 544,000 Å3 volume calculated 
from the structure of the E65R cage using the Voss Volume Voxelator program113 is 
roughly 10% smaller than the 600,000 Å3 calculated for a polyALA version of wt (PDB 
ID 1SQ3)49 – a finding also reflected in our TEM and DLS results (Table 2.1). These 
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volumes correspond to outer diameters of 10.1 nm and 10.5 nm for E65R and wt, 
respectively.  
 
Figure 2.17. E65R exists exclusively in its 24-mer state in a closed-pore assembly. a) Cartoon of 
E65R crystal structure with residue 65 highlighted in purple. b) Open-pore wt AfFtn (PDB 1SQ3) 
with residue 65 highlighted in purple. 
 
Exploring E65R Stability Through Mutagenesis 
 Because our crystal structure does not have high enough resolution to observe 
individual sidechains, we decided to further investigate the enhanced stability of E65R via 
mutagenesis. R65 is predicted to form a salt bridge with D138 on a neighboring subunit. If 
that salt bridge interaction alone causes the enhanced stability observed, removing it should 
restore wt-like self-assembly in E65R. To test this, we made a double mutant 
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E65R/D138N, which we expressed, purified, and characterized. By DLS and Trp 
fluorescence, we saw very similar behavior to the single mutant E65R, with intact assembly 
at low ionic strengths (Figure 2.18).  
 
Figure 2.18. Self-assembly characterization of E65R/D138N. a) Dynamic light scattering shows 
predominantly 24mer at high (violet bars) and low (blue bars) ionic strength. b) Tryptophan 
fluorescence shows little disassembly upon low ionic strength incubation. Violet line is 800 mM 
NaCl, blue line is 0 mM NaCl.  
 
 Computations for E65R/D138N show that R65 rotates upward to salt bridge with 
E131 instead of D138 (Figure 2.19), likely maintaining the enhanced cage stability. 
Although mutation could be done to prevent salt bridging to E131, E131 is in a pocket of 
negatively charged residues that are all within salt bridging distance of R65. Elimination 
of one would probably result in R65 shifting to another. Extensive mutagenesis to remove 
all possible salt bridging partners of R65 is likely to result in significant perturbation of the 
protein structure and would yield little information on the root cause of E65R enhanced 
stability. Thus, a higher resolution crystal structure is needed to more fully explain the 
unique behavior of E65R.  
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Figure 2.19. Possible salt bridges for E65R and E65R/D138N. a) R65 can pair with D138 on a 
neighboring subunit, potentially leading to enhanced stability observed. b) When D138 is mutated 
to N138, R65 is predicted to rotate upward toward E131 and form a salt bridge, maintaining the 
enhanced stability.  
 
Gold Nanoparticle Encapsulation  
Having established differences in self-assembly patterns for the various proteins, 
we next investigated their interaction with 5 nm AuNPs coated in bis- (p-
sulfonatophenyl)phenylphosphine (BSPP). We showed previously that BSPP-coated, 5-nm 
AuNPs are more stably encapsulated within wt-AfFtn compared to citrate-coated AuNPs.51 
To encapsulate the NPs, we first incubated the proteins at 0 mM NaCl overnight at 4 °C to 
allow for maximum disassembly. We then added AuNPs and incubated for 48 h at room 
temperature with gentle agitation. After 48 h the presence of AuNP did not disrupt the 2° 
structure of any of the proteins when incubated at a ratio of 1:1 AfFtn 24mer:AuNP (Figure 
2.20).  
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Figure 2.20. CD spectroscopy shows minimal changes in secondary structure upon 48 h incubation 
with AuNPs. Sample concentration was 0.1 mg/mL protein, 0.2 µM AuNP to minimize AuNP 
scattering artifacts.  
However, by native agarose gel electrophoresis some differences were observed 
among the samples. By 48 h, wt, A127R, and D138K appeared to successfully encapsulate 
AuNPs as judged by cleanly overlapping blue protein and red AuNP bands, while the 
AuNP bands in the E65R-containing sample remained diffuse (Figure 2.21).  
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Figure 2.21. Native gel electrophoresis time course for AfFtn-AuNP samples. Samples were 0.6 
µM AfFtn, 0.6 µM AuNP in 20 mM phos (pH 7.6).  
Shown in Figure 2.22, successful AuNP encapsulation was observed for wt, 
A127R, and D138K at a ratio of 1:1 AfFtn 24mer:AuNP and higher. In contrast, the AuNP 
bands for the E65R-containing samples were significantly more diffuse, indicating greater 
variety in particle charge:mass ratio. Two bands are visible in the Coomassie stained image, 
with the less intense band overlapping with the darkest part of the AuNP bands. This 
suggests that although some AuNPs are encapsulated within the E65R cavity, many are 
not, likely due to less disassembly of the protein cage.  
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Figure 2.22. Native gel electrophoresis for AfFtn-AuNP samples at varying stoichiometries. AuNP 
association is seen for wt, A127R, and D138K at ratios of 1:1 AfFtn 24mer:AuNP, but not E65R, 
which shows lower propensity for disassembly.  
 
 We investigated the ability of the protein to stabilize the AuNPs against salt-
induced aggregation. With increasing ionic strength, electrostatically-stabilized AuNPs 
begin to aggregate, causing a red shift in the surface plasmon resonance (SPR) peak.114 By 
monitoring the SPR peak with increasing concentration of NaCl, we could observe how 
well the proteins passivated the AuNP surface (Figure 2.23). Bare AuNPs had the largest 
SPR red-shift of over 40 nm, from 0 to 800 mM NaCl. E65R-AuNP had the next largest 
shift of approximately 20 nm, while wt-AuNP, A127R-AuNP, and D138K-AuNP all had 
similarly small red shifts of less than 10 nm. This suggests that E65R does not passivate 
the surface of the AuNP, in agreement with the native gel results. As a 24mer, E65R likely 
interacts with the AuNP surface, providing a smaller stabilizing effect compared to wt, 
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A127R, and D138K. By TEM (Figure 2.24), several 24mer cages can be seen in contact 
with the AuNP surface, supporting this hypothesis.  
 
Figure 2.23. AuNP salt stability assay. Changes in SPR peak maximum with respect to salt 
concentration show higher stability for AuNPs that appear associated with proteins by gel.  
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Figure 2.24. TEM micrograph of E65R-AuNP sample, showing 24mer cages near AuNP surface 
(highlighted in red circles).  
 We also explored the AuNP templating ability of the protein, after encapsulating a 
preformed 5-nm AuNP. By adding additional gold salt and reducing agent, the AuNP can 
be further grown inside the AfFtn cavity, with the protein acting as a template to constrain 
growth.51 As shown in Table 2.2 and Figure 2.25, all of the proteins with high encapsulation 
yields showed controlled particle growth to ~7 nm with narrow size distributions. As 
expected, E65R-AuNP had a comparatively wider size distribution and larger average 
particle size. The UV-vis spectra of the templating samples also showed differences 
between high-encapsulating and low-encapsulating proteins (Table 2.2 and Figure 2.26). 
Whereas wt, A127R, and D138K all had post-growth SPR peak positions unchanged from 
the initial 519 nm, the E65R sample redshifted to 524 nm, indicating a small amount of 
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aggregation. The SPR peak width is indicative of particle size distribution, with narrower 
peaks corresponding to narrower distributions. The SPR width decreased after templating 
for the wt, A127R, and D138K samples, but increased for E65R, supporting TEM results 
that suggest a broader AuNP size distribution. These results suggest that wt, A127R, 
D138K successfully encapsulate the AuNP and template further growth, whereas E65R is 
more selective and encapsulates fewer NPs, resulting in less templated growth. 
 
 
Figure 2.25. TEM micrographs post-particle growth. Insets show normalized size distributions 
based on TEM images. Yellow bars are pre-growth samples, blue bars are post-growth. Scale bars 
are 100 nm. 
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Table 2.2. Gold nanoparticle templating summary 
Sample Davg AuNP (nm)a Nb SPR post-growth 
(nm) 
Change in SPR 
width (nm)c 
wt-AuNP 7.2 ± 1.1  366 519 -8 
A127R-AuNP 6.8 ± 0.7 464 519 -10 
D138K-AuNP 6.8 ± 0.7 379 519 -10 
E65R-AuNP 7.2 ± 1.8 224 524 4 
aAverage diameter of AuNPs post-templated growth.  
bNumber of particles measured using the Analyze Particles feature of ImageJ111 to calculate average 
diameter. 
cAs calculated by 2x the half-width, half-max of the peak.  
 
 
Figure 2.26. UV-vis spectra for AuNP templating. Pre-growth spectra are in yellow, post-growth 
spectra are in blue.  
2.3 Discussion 
 We have expressed and characterized three novel AfFtn mutants, each replacing a 
negative or neutral residue with one that is positively charged. None of the mutations 
decreased the thermal stability nor hampered the ability of the protein to self-assemble into 
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a nanocage at high ionic strengths. However, the results presented here demonstrate the 
profound effect a single point mutation can have on the self-assembly of AfFtn. This is in 
keeping with recent literature, where E. coli bacterioferritin,38 ferritin-like DNA binding 
protein from starved cells (Dps),37 and bullfrog ferritin43 were also shown to be susceptible 
to changes in self-assembly through minor mutagenesis. While the AfFtn mutations 
changing a negative residue to a positive one (D138K and E65R) showed increased 24mer 
population in low ionic strength solutions, changing a neutral residue to a positive one 
(A127R) showed similar behavior to wt, and even slight destabilization of the 24mer. Even 
between D138K and E65R there were significant differences in the favorability of 24mer 
assembly, with E65R remaining >90% 24mer in all salt concentrations tested and D138K 
disassembling at low salt conditions. The specific interdimer location of the point mutation 
greatly affects self-assembly. 
 It is notable that E65R shows enhanced subunit thermal stability in addition to its 
assembly stability. Increased thermal stability can often go hand-in-hand with enhanced 
cage stability. For example, when the self-assembly equilibrium of E. coli bacterioferritin39 
was shifted from a mixture of dimer and 24mer to 100% 24mer, the Tm increased by over 
20 °C. The inverse can also be true, as destabilization in favor of dimers has led to 
decreased thermal stability in mycobacteria ferritin,115 E. coli ferritin A,42 Dps,37 and E. 
coli bacterioferritin.38 However, in E. coli bacterioferritin, mutations designed to plug an 
interdimer water pocket with hydrophobic residues led to significantly enhanced thermal 
stability (DTm >20 °C) and yet greater dimer population compared to the wt, as the 
geometry of the more stable dimers prevented cage formation.40 Although A127R appears 
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to favor dimer more than wt at low-salt conditions, its subunit thermal stability is identical. 
For D138K, its enhanced 24mer stability at low-salt conditions also does not appear to be 
linked to thermal stability, as it too exhibits the wt Tm.  
All our results support enhanced cage stability for E65R and D138K at low ionic 
strengths. The symmetry shift seen in the crystal structure of E65R is striking (Figure 
2.27a) but cannot alone explain the enhanced cage stability. A double mutant of AfFtn, 
K150A/R151A, was previously shown to change the cage symmetry to octahedral; 
however, it maintained the salt-dependent disassembly and reassembly behavior of the wt 
protein.116 It is remarkable that in our study a single point mutation led to such a dramatic 
change in assembly behavior. This symmetry shift can be rationalized using the 
computationally predicted side chain conformation of R65. In the tetrahedral assembly, the 
amino acid exists in two distinct environments due to the symmetry of the cage. In one 
environment, R65 on one subunit is positioned directly across from R65 of a neighboring 
subunit (Figure 2.27b), resulting in electrostatic repulsion. In the octahedral assembly, 
however, R65 is in only one environment, highly similar to the 3-fold axis in the open pore 
wt, and the residue is not in proximity to an R65 residue on a separate protomer, which is 
consistent with octahedral assembly being preferred. Within the model of E65R, R65 and 
D138 form a salt-bridge at the interface present in both the tetrahedral and octahedral 
assemblies (Figure 2.27c), which could lead to the enhanced cage stability observed. 
A127R was also predicted to form complementary electrostatic interactions (Figure 2.27d). 
However, Arg127 is conformationally constrained at an interface that is more sterically 
crowded than the pore environment where the mutations E65R and D138K were 
introduced. With A127R, this introduction of a large residue at a subunit interface may 
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reduce the stability of the 24mer at low-salt concentrations relative to the wild type. Within 
the model of D138K, a K138-D34 salt bridge is observed between neighboring subunits, 
which may increase the population of 24mer relative to wild type (Figure 2.25e).  
 
Figure 2.27. Inter-protomer interactions in mutants of AfFtn. Crystallographic structures of AfFtn 
with site 65 highlighted as purple sphere (a, b). (a) Crystallographic structure for E65R reported 
herein (closed form, octahedral structure). (b) Structure of wt AfFtn (PDB ID 1SQ3) (open pore, 
tetrahedral structure). Two R65 are in close proximity at one interface. (c-e) Computationally 
modeled structures of mutants with most probable conformations of mutated side chains.  Distinct 
protomers (chains) have different colors: cyan, yellow, and pink. (c) Within E65R, potential R65-
D138 salt bridge. (d) Within A127R, a potential R127-E65 salt bridge within a sterically crowded 
local environment. (e) Within D138K, a potential K139-D34 salt bridge. 
 
 Both mutants capable of disassembly (A127R, D138K) showed interaction with 
AuNPs by gel, unlike E65R, which does not disassemble. It is interesting that we see 
changes in self-assembly kinetics for the proteins alone, and yet in the presence of AuNPs, 
protein assembly encapsulating the AuNP seems to be similarly fast for wt, A127R, and 
D138K. High ionic strength solution perhaps does not model the charged AuNP surface 
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and thus differences seen in protein-only assembly are not observed in the presence of 
AuNPs. We hypothesize that the AuNP nucleates protein assembly at its surface and may 
thereby increase the effective concentration of protein in solution. Our DLS results suggest 
that protein concentration has a large effect on the rate of protein cage assembly, with 
decreasing concentration paradoxically leading to faster assembly. This is likely due to 
minimal aggregation of dimers at low concentrations, allowing assembly to occur. We were 
unable to monitor reassembly by DLS at 0.3 mg/mL due to low signal-to-noise ratio, but 
based on our results from 1, 2, and 5 mg/mL samples, we would expect assembly to occur 
rapidly at 0.3 mg/mL for all three proteins that disassemble.  
 When NPs are introduced into a biological medium, protein adsorption is rapid and 
evolves with time. This shell of protein on the surface of NPs is termed the protein corona.64 
Protein adsorption has been shown to sterically stabilize NPs against aggregation with 
increasing salt concentration,72,117 similar to our results. A127R, D138K, and wt protein all 
successfully encapsulated AuNPs as seen by native gel, prevented aggregation of AuNPs 
with increasing ionic strength compared to particles without protein present, and enabled 
effective AuNP templating. Although E65R does not encapsulate AuNPs at the same high 
yields as the disassembling proteins, there is still some level of AuNP stabilization, as the 
SPR red shift for the E65R-AuNP sample was smaller compared to bare particles. The 
fully-assembled E65R cage may be adsorbed to the NP surface, which does not provide 
full encapsulation, but may be enough to somewhat stabilize the particle. This hypothesized 
adsorption is also not enough to prevent less controlled particle growth upon addition of 
gold salt and reducing agent. It is possible that the cage dynamics of E65R are such that 
some AuNPs are encapsulated, as indicated by faint bands overlapping by native gel 
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(Figure 2.21 and 2.22). Such is the case for lumazine synthase from Aquifex aeolicus, a 
protein cage capable of encapsulating large cargo without first disassembling.118 The 
greater 24mer stability and cargo selectivity exhibited by E65R opens up the possibility of 
designing more specific ferritin-cargo interactions in the future. We are beginning to 
explore new types of cargo for ferritin encapsulation. 
2.4 Conclusions 
 We have shown that single point mutations of AfFtn can have varying effects on 
thermal stability, assembly symmetry, and self-assembly equilibrium, kinetics, and 
reversibility. More dramatic charge changes such as changing negatively charged residues 
to positive ones increased the stability of the 24mer in decreasing ionic strength, while a 
less dramatic change, changing a neutral residue to a positive one, had a slightly 
destabilizing effect. The E65R mutant shows enhanced cage formation as well as thermal 
stability, formation of the 24mer at low salt conditions, and self-assembly in octahedral 
symmetry rather than tetrahedral. The kinetics of self-assembly were also affected by 
mutation, with A127R showing slower nanocage assembly compared to wt, and D138K 
assembling faster. These results corroborate earlier studies in other ferritin species, 
demonstrating the generality of single point mutations along subunit interfaces 
dramatically affecting cage self-assembly. All mutants showed some salt stabilization of 
AuNPs compared to bare particles, but only mutants that retained their ability to 
disassemble showed full AuNP encapsulation and well-controlled templated AuNP 
growth. Enhanced control over protein cage assembly could have applications in delivery, 
nanomaterials separations, and controlled inorganic NP synthesis. 
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2.5 Experimental Procedures 
Computational design of AfFtn mutants. Using atomic coordinates from chains 
G, H and J of the crystallographic structure of Archaeoglobus fulgidus thermophilic ferritin 
(PDB ID 1SQ349), amino acid probabilities were calculated independently for sites 34, 65, 
127, 131, and 138. Sites 127, 131, and 138 are situated along a helical interfacial region. 
Sites 34 and 65 were chosen as they form, along with site 138, the center of a carboxylate-
rich pore. Eighteen natural amino acids were considered at each site selected; cysteine and 
proline were precluded. For each mutation calculation, residues other than the site of 
interest were constrained to the crystal structure conformations. Side-chain conformational 
states of mutated sites were taken from a rotamer library.119,120 An entropy-based, 
probabilistic formalism was used to calculate the probabilities of the amino acids and their 
rotamer conformations.121–124 Using CHARMM19,119 hydrogen atoms were added, and 
energies were calculated using the dihedral, van der Waals, and electrostatic terms, with a 
non-bonded cut-off of 8 Å. The probabilistic approach has an effective parameter β that is 
conjugate to the average energy over sequences and side chain conformations; β = 0.5 
mol/kcal for these calculations.121–123 The probability of each amino acid at a mutated site 
was the sum of the calculated probabilities of its side-chain conformations. 
Mutagenesis. Site-directed mutagenesis was used to generate the mutant AfFtn 
plasmids using the Quik Change kit (Stratagene). Primers used to generate the mutations 
were purchased from Integrated DNA Technologies and are listed below: 
E65R 
Forward (5ʹ-3ʹ): GATTTCGTTTCCCGTCGCGGTGGCCGTG 
Reverse (5 ʹ-3ʹ): CACGGCCACCGCGACGGGAAACGAAATC 
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A127R 
Forward (5ʹ-3ʹ): CTGCAGTGGTACGTTCGTGAACAAGTGGAAG 
Reverse (5ʹ-3ʹ): CTTCCACTTGTTCACGAACGTACCACTGCAG 
D138K 
Forward (5ʹ-3ʹ): GGAGGAAGCCTCTGCCCTCAAAATTGTGGAGAAGCTGAGG 
Reverse (5ʹ-3ʹ): CCTCAGCTTCTCCACAATTTTGAGGGCAGAGGCTTCCTCC  
E65R/D138N (used E65R plasmid as the template, the following primers inserted D138N 
mutation):  
Forward (5ʹ-3ʹ): GTTTCTCAACGATGTTCAGGGCGCTCGCTTC 
Reverse (5ʹ-3ʹ): GAAGCGAGCGCCCTGAACATCGTTGAGAAAC 
Mutations were confirmed using Sanger Sequencing on ABI 3730, provided by the DNA 
Sequencing Facility at the University of Pennsylvania.  
Protein expression and purification. The plasmids were transformed in E. coli 
BL21-CodonPlus(DE3)-RP cells and cultured overnight in LB medium at 30 °C, 
supplemented with 100 μg/mL ampicillin and 35 μg/mL chloramphenicol. The cultures 
were then transferred to 1 L terrific broth (TB) supplemented with the same antibiotics and 
grown at 37 °C until OD600 reached ~0.6-0.8. The cells were then induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 h. Cells were lysed by treating with 
lysozyme at rt for 30 min, followed by sonication. The cell-free extract was obtained by 
centrifugation (30 min, 6 krpm, 4 °C), and after adding MgCl2 to a final concentration of 2 
mM, the supernatant was treated with DNAse for 15 min at rt. The solution was then heat 
shocked at 80 °C for 10 min and soluble protein was obtained following centrifugation (1 
h, 9 krpm, 4 °C). The supernatant was filtered and buffer exchanged to assembly buffer (2 
M NaCl, 1 mM EDTA, 20 mM phos, pH 7.6). The protein was concentrated and injected 
onto a HiLoad 16/60 column equilibrated with high-salt buffer (800 mM NaCl, 20 mM 
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phos, pH 7.6). Purity was confirmed using SDS-PAGE (4–15% tris–HCl, Mini-Protean 
TGX gel). By UV-vis spectroscopy no significant DNA contamination was observed. 
Identify was confirmed using matrix-assisted laser desorption ionization-time of flight 
mass spectrometry (MALDI-TOF MS), using sinapinic acid as a matrix and linear positive 
mode ion generation. Protein concentration was determined using the Bradford Assay, with 
bovine gamma globulin as a standard. Average protein yield was 12 mg/L TB.  
Transmission electron microscopy (TEM). TEM samples were prepared using 
glow-discharged carbon-coated copper grids (Electron Microscopy Sciences). The grids 
were floated on 5 μL of sample for 5 min, washed with 2 drops of distilled water, and 
stained with 2% ammonium molybdate or uranyl acetate. Micrographs were obtained using 
a Tecnai T12 electron microscope operating at 120 keV. Images were analyzed using 
ImageJ.111 
Circular dichroism spectroscopy (CD). CD data were obtained using an Aviv 410 
CD spectrometer (Aviv Biomedical; Lakewood, NJ) with 1 mm quartz cuvette (Hellma 
USA). Protein samples were 0.3 mg/mL in high-salt buffer. For melting point 
determination, the signal at 222 nm was monitored as temperature increased 1-96 °C, with 
a 1 min equilibration at each 1 °C step. Signal was averaged over 10 s at each temperature.  
Differential scanning calorimetry (DSC). A VP-DSC microcalorimeter was used 
to measure the Tm of E65R and wt proteins. Buffer scans were run overnight prior to sample 
measurement. Samples of 0.5 mg/mL protein in high-salt buffer were degassed with 
stirring at 10 °C before loading into the sample chamber. The temperature range was 10-
125 °C with a scan rate of 60 °C/h.  
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Ferroxidase activity assay. Ferritin samples were buffer exchanged to 25 mM tris 
(pH 7.0) and diluted to 0.1 mg/mL, 800 µL total volume. A fresh solution of 10 mM FeSO4 
was prepared in 5 mM HCl to prevent premature oxidation. Ferroxidase activity was 
monitored at 315 nm and 37 °C with stirring using an Agilent 8453 UV-visible 
spectrometer. The absorbance was measured at 10 s intervals over a total time of 600-800 
s, adding 480 eq iron per AfFtn 24mer after an initial ~20 s.  
Tryptophan fluorescence. Steady-state fluorescence spectra were collected on a 
Varian Cary Eclipse fluorescence spectrophotometer (Cary Eclipse software, 2003) using 
100 μL quartz cuvette (Starna Cells). Protein samples were prepared at 5 mg/mL and 
incubated overnight at 4 °C in the appropriate high-salt or no-salt buffer (20 mM phos, pH 
7.6). Samples were excited at 295 nm, scanned 300-400 nm, with a PMT voltage of 700-
750 V, at 25 °C. 
Dynamic light scattering (DLS). DLS data were collected on a Zetasizer Nano ZS 
(Malvern). Protein samples (5 mg/mL) were prepared in 0.22 μm filtered high-salt or no-
salt buffer and incubated overnight at 4 °C. The measurements were done in plastic micro 
cuvettes at 25 °C, with backscatter detection at an angle of 173°.  
Size exclusion chromatography (SEC). Samples of 5 mg/mL protein were 
prepared in 20 mM phos (pH 7.6), varying concentrations of NaCl, and incubated overnight 
at 4 °C. Samples of 200 µL were injected onto a Superdex200 Increase 10/300 GL column 
equilibrated with the same buffer, using an ATKA FPLC (GE Healthcare). The samples 
were run at 4 °C with flow rate of 0.9 mL/min.  
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Native gel electrophoresis. For PAGE analysis, 2.4 µg protein was loaded onto 4–
20% tris–HCl gels (Mini-Protean TGX) and run at 150 V for 90 min, on ice. The running 
buffer was tris-glycine (25 mM tris, 192 mM glycine, pH 8.3). Agarose gels (0.7%) were 
run at 100 V for 20 min at room temperature, with 5 mM NaCl, 20 mM phos (pH 7.6) as 
the running buffer.  
X-ray crystallography. Crystals of E65R were prepared by mixing 2 µL of protein 
solution (10 mg/mL E65R in high-salt buffer) with 2 µL of precipitant solution (0.45 M 
potassium phosphate monobasic, 0.3 M sodium phosphate monobasic, 5% (v/v) glycerol) 
in a sitting drop suspended over a 500 µL reservoir of precipitant solution. The sitting drop 
was streak seeded with E65R crystals previously grown in the same conditions. The 
crystallization tray was incubated at 21 °C, and large octahedral crystals appeared within 
24 h. Single crystals of E65R were briefly immersed in cryoprotectant solution (0.8 M 
potassium phosphate monobasic, 0.8 M sodium phosphate monobasic, 20% (v/v) glycerol) 
before being flash-cooled in liquid nitrogen. X-ray diffraction data from single crystals of 
E65R were collected at beamline 9-2 at the Stanford Synchrotron Radiation Lightsource 
(SSRL). Diffraction data were integrated using iMosflm125 and processed using 
AIMLESS126 from the CCP4 suite of programs.127 The structure of E65R was phased in 
PHENIX128–130 by molecular replacement using a monomer of wild-type AfFtn (PDB ID 
1SQ3).49 Structure refinement was performed in PHENIX and manual model adjustments 
were made in COOT.131 Initial rounds of refinement showed ambiguous density in the 2Fo-
Fc map for protein sidechains, so a polyALA model for E65R was used in which all protein 
sidechains were replaced with alanine. The lack of density in the Fo-Fc difference map 
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after refinement with polyALA E65R affirmed that sidechain conformations could not be 
confidently assigned based on experimental data. Refinement proceeded until Rfree 
converged at its lower limit. The quality of the final model was assessed using 
MolProbity132 and the wwPDB validation server. Data collection and refinement statistics 
are recorded in Table 2.3. Figures were generated using PyMOL.133 
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Table 2.3. Data collection and refinement statistics 
 AfFtn E65R 
wavelength (Å) 0.979 
resolution limits (Å)a 99.15 – 3.08 (3.25-3.08) 
unit cell  
       space group P213 
       a, b, c (Å) 171.7, 171.7, 171.7 
       α, β, γ (°) 90.0, 90.0, 90.0 
total/unique 
reflections 566942/31499 
multiplicitya 18.0 (18.9) 
Rmergea,b 0.164 (1.031) 
Rpima,c 0.056 (0.348) 
CC1/2a,d 0.999 (0.570) 
I/σ(I)a 15.0 (3.6) 
completeness (%)a 100 (100) 
Rworke 0.26 
Rfreef 0.28 
root-mean-square 
deviations  
       bonds (Å) 0.003 
       angles (°) 0.891 
Ramachandran plot 
(%)g  
       favored 91.2 
       allowed 8.7 
       outliers 0.2 
PDB accession code 5V5K 
a Values in parentheses refer to the highest-
resolution shell of the data. 
b Rmerge = ∑|Ih – ⟨Ih⟩|/∑⟨Ih⟩; Ih = intensity measure for 
reflection h; ⟨Ih⟩ = average intensity for reflection h 
calculated from replicate data. 
c Rpim = ∑(1/(n – 1)1/2|Ih - ⟨Ih⟩|/∑⟨Ih⟩; n = number of 
observations (redundancy). 
d CC1/2 = στ2/(στ2 + σε2), where στ2 is the true 
measurement error variance and σε2 is the 
independent measurement error variance. 
e
 Rwork = ∑||Fo| - |Fc||/∑|Fo| for reflections contained 
in the working set. |Fo| and |Fc| are the observed 
and calculated structure factor amplitudes, 
respectively.  
f
 Rfree = ∑||Fo| - |Fc||/∑|Fo| for reflections contained in 
the test set held aside during refinement (5% of 
total). 
g calculated by MolProbity 
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Salt stability assay. 5-nm citrate-capped AuNPs were purchased from TedPella. 
Ligand exchange to BSPP was performed as previously published.51 Protein-AuNP 
samples were prepared by first disassembling AfFtn overnight in no-salt buffer at 4 °C. 
Disassembled protein was mixed with AuNPs to a final concentration of 0.6 µM AfFtn, 
0.6 µM AuNP in 0 mM NaCl buffer. The sample was incubated at rt with gentle agitation 
(gel rocker) for 48 h. After incubation, 50 µL sample was mixed with 50 µL increased salt 
buffer (0, 400, 800, 1200, 1600 mM NaCl, 20 mM phos, pH 7.6) for final salt 
concentrations of 0, 200, 400, 600, 800 mM NaCl. UV-vis spectra were collected using an 
Infinite M1000 microplate reader (Tecan).  
Gold nanoparticle templating. AuCl3 (10k equivalents) were added to protein-
AuNP samples (0.6 µM AfFtn, 0.6 µM AuNP) and incubated at rt for 3 h. Samples were 
then desalted on a 10DG column pre-equilibrated with 0 mM NaCl buffer to remove excess 
AuCl3. Pink fractions containing protein-AuNP were combined and 30k equivalents of 
freshly prepared ascorbic acid were added. Samples were incubated overnight at rt and 
characterized by UV-vis and TEM. TEM micrographs were analyzed using the Analyze 
Particles function in ImageJ,111 with 5-infinity nm2 as the particle area range and 0.5-1.0 
as the circularity. 
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CHAPTER 3: STRUCTURAL-FUNCTIONAL ANALYSIS OF ENGINEERED 
PROTEIN-NANOPARTICLE ASSEMBLIES USING GRAPHENE 
MICROELECTRODES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The content of this chapter has been submitted for publication. It has been adapted here: 
 
Reprinted with permission from Ping, J.; Pulsipher, K.W.; Vishnubhotla, R.; Villegas, J.A.; 
Hicks, T.L.; Honig, S.; Saven, J.G.; Dmochowski, I.J.; Johnson, A.T.C. Structural-
Functional Analysis of Engineered Protein-Nanoparticle Assemblies Using Graphene 
Microelectrodes. 2017. Submitted. 
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3.1 Introduction 
The ability to attach functional biomolecules to nanoparticle surfaces has spurred 
development of nano-therapeutic,94 diagnostic,134 and biosensing agents,135,136 as well as 
novel nano-structures137 and devices.138 Methods for controlling the number and 
orientation of oligonucleotides and peptides at nanoparticle surfaces have been 
established,138 but it remains challenging to create nanoparticle-protein assemblies with 
native-like protein structure and function.139 One emerging paradigm is a thermophilic 
ferritin protein140,141 whose 24 self-assembling four-helix bundles maintain native 
stoichiometry and secondary structure when encapsulating a single 5-nm gold nanoparticle 
(AuNP).50–52 However, the assembly configuration in solution (i.e. protein quaternary 
structure) remains unknown because conventional methods for characterizing protein 
structure, such as X-ray crystallography,105 are not suitable for liquid-phase protein-
nanoparticle conjugates. Here, we demonstrate a non-perturbing method using a graphene 
microelectrode142 for structural-functional analysis of an ordered AuNP-ferritin protein 
assembly that differs substantively from an unstructured protein corona. Ferritin is a 
multimeric iron-storage protein comprising 24 identical protein subunits and featuring a 
large (~8-nm) interior compartment separated from the exterior solution by a protein shell. 
The Archaeoglobus fulgidus ferritin (AfFtn) used here is a unique archaeal ferritin that 
forms a tetrahedral arrangement of its four-helix-bundle subunits, yielding four wide (4.5-
nm), triangular pores spanning the 2-nm protein shell49 (Figure 3.1a). Stoichiometric 
addition of 5-nm gold nanoparticles (AuNPs) to disassembled apo-AfFtn induces AfFtn 
assembly around individual AuNPs capped with bis(p-sulfonatophenyl)phenylphosphine 
(BSSP),50–52 while maintaining its native thermal stability, stoichiometry, ferroxidase 
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activity, and secondary structure.51 Charge flowing from the AuNP through ferritin pores 
transfers into the graphene microelectrode and is recorded by an electrometer. The 
measurements are consistent with a pore diameter of 4.5-nm, providing evidence that 
ferritin maintains native-like quaternary structure when complexed with AuNP. This work 
demonstrates a new tool for probing the nano-bio interface, and highlights the design and 
characterization of nanoparticle-protein assemblies with tunable ionic conductivity and 
chemical reactivity. 
3.2 Results and Discussion 
	
 
Figure 3.1. Graphene microelectrode setup. a) Schematic of the setup for measuring spontaneous 
Faradaic charge transfer across a pore to a graphene microelectrode in buffer solution and circuit 
diagram. b) Faradaic current as a function of electrostatic potential in the buffer solution above 
graphene. The red line is a linear fit to the data. 
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A graphene microelectrode was used to quantify Faradaic current through a ferritin-
AuNP assembly and to differentiate between open- and closed-pore forms of the AfFtn 
shell.  The experimental setup (Figure 3.1a) consisted of a graphene-based microelectrode 
connected to the inverting input of an electrometer142 (Keithley 6517a). The electrostatic 
potential above a protein assembly in fluid, 𝜓0, drives a sub-picoampere Faradaic current, 
i, through the series resistance of the charge-transfer at the graphene-solution interface142 
(𝑅23 ~ 100 GΩ), the graphene sheet (𝑅☐ ~ 102 – 103 Ω/☐), and the graphene-gold 
contact143 (𝑅2 ~ 10 Ω). Transferred charge accumulates on the feedback capacitor and is 
read out on the electrometer. Because there is no extrinsic bias voltage between the solution 
and the microelectrode, heat dissipation (aW µm-2) and electrical perturbation (~pA) to the 
protein structure144 are minimized. 
Detecting AfFtn Disassembly via Graphene Microelectrode 
To interrogate our AfFtn-AuNP system, we first recorded the buffer response. The 
Faradaic current 𝑖	 is proportional to the potential 𝜓0: 𝑖 = 𝜓0/𝑅23. We applied a phosphate 
buffer solution to the graphene microelectrode and measured the Faradaic current while 
the electrostatic potential above the graphene surface was tuned by varying the buffer ionic 
strength 𝑐 (Figure 3.1b). The variation of 𝜓0 with ionic strength was inferred from the 
Grahame equation for the electric double layer.145 The fit to the data corresponds to a 
constant charge-transfer resistance 𝑅23 = 69 ± 2 GΩ, and the fit passes through the origin 
as expected (0.6 ± 0.9 fA). 
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Figure 3.2. Graphene microelectrode can distinguish between assembled and disassembled 
ferritin. a) Time trace of the charge transfer between a graphene microelectrode and mutant A. 
fulgidus E65R ferritin solution (AfFtn-R), and wild-type A. fulgidus ferritin solution (AfFtn). The ionic 
strength of the solution increases as the grey-level of the data increases. b) Faradaic current for 
AfFtn-R (black circles) and AfFtn (red squares) based on the data in panel a). The black curve is a 
fit to the data for AfFtn-R using Equation 3.2. c) Faradaic current difference for AfFtn compared to 
AfFtn-R; the red curve is a fit based on Equation 3.3.  
 
We next recorded a baseline response for assembled AfFtn. We measured the 
Faradaic current of an AfFtn mutant (E65R, termed AfFtn-R), which remains a 24mer even 
in low ionic strength solution (see Chapter 2). The solution (200 µL; 0.6 µM) was applied 
to the microelectrode, and a sparse layer of non-specifically bound protein allowed to form 
and equilibrate (Figure 3.3).  
 
Figure 3.3. TEM image of ferritin non-specifically adsorbed on graphene. The light gray 
background is a sheet of monolayer graphene. Dark dots are individual ferritin cages. 
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As the ionic strength of the solution was varied from 40 mM to 640 mM, a 15-sec 
time trace of Faradaic charge transfer (Figure 3.2a) for AfFtn-R or AfFtn was used to 
extract the corresponding Faradaic current (Figure 3.2b). The solutions showed nearly 
identical Faradaic current at high ionic strength where both ferritins form stable 24mer 
assemblies, but the currents differed significantly at low ionic strength, where only AfFtn 
disassembles into dimers. The measured current for the AfFtn-R solution (black circles in 
Figure 3.2b) and the Faradaic current difference between the solutions of AfFtn and AfFtn-
R (Figure 3.2c) are well explained by models based on known properties of the electric 
double layer and AfFtn assembly.  
The Grahame equation145 can be written as: 
𝜓0 	= 2𝑘B𝑇𝑒 sinh=$ 𝜎?8𝜀𝜀A𝑘B𝑇𝑐  (3.1) 
where 𝑘B is Boltzmann’s constant, 𝑇 the absolute temperature, 𝑒 the electronic charge, 𝜀 
(𝜀A) the relative (vacuum) permittivity, and 𝜎? the areal charge density in the solution above 
the graphene, and c the solution ionic strength. This leads to: 
𝑖	 = −1𝑅23 ∙ 2𝑘B𝑇𝑒 sinh=$ 𝜎?8𝜀𝜀A𝑘B𝑇𝑐  (3.2) 
The data in Figure 3.2b are well fit by Equation 3.2. The best fit values for 𝑅ct,24mer 
and 𝜎d,24mer are 232 ± 74 GΩ and -0.07 ± 0.03 C m-2, respectively. Compared to the fit 
values obtained for an experiment conducted in pure phosphate buffer (𝑅ct= 65 ± 3 GΩ, 𝜎d=-0.031 ± 0.003 C m-2), there is an increase of the negative charge areal density due to 
the negative charge carried by AfFtn-R, accompanied by an increase in the charge transfer 
resistance due to the inhibition of charge communication by charged AfFtn-R 
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molecules.146,147 Given the measured areal number density of non-specifically adsorbed 
ferritin on graphene, ~3500 µm-2 (Figure 3.3), the effective negative charge carried by each 
AfFtn-R 24mer is ~40, smaller than the value estimated by the pKa values of the residues 
of AfFtn-R, ~110. This is not surprising as charges on ferritin far from the graphene should 
be screened by ions in solution.148  
The Faradaic current measured for AfFtn solution differs significantly from that for 
AfFtn-R solution. Unlike AfFtn-R, which remains assembled across the range of ionic 
strengths tested, AfFtn disassembles into dimers at low ionic strength with a portion of 
E 2$FE 2, where 𝐾 is the dissociation constant for AfFtn.50 The inverse of the charge transfer 
resistance 1 𝑅ct and the surface charge density 𝜎s for the graphene/AfFtn solution interface 
are the sum of these quantities for the dimers, 1 𝑅ct,dimer and 𝜎s,dimer, and those for the 24-
mers, 1 𝑅ct,24mer and 𝜎s,24mer, weighted by E 2$FE 2 and $ 2$FE 2 , respectively. The current 
difference can then be written as: 
Δ𝑖 = 2𝑘B𝑇𝑒𝑅ct sinh=$ 𝜎s8𝜀𝜀A𝑘B𝑇𝑐 − 2𝑘B𝑇𝑒𝑅ct,24mer sinh=$ 𝜎s,24mer8𝜀𝜀A𝑘B𝑇𝑐  (3.3) 
The measured current for the AfFtn-R solution is well fit by Equation 3.2 with best 
fit values of 𝑅23 (232 ± 74 GΩ) and 𝜎? (-0.07 ± 0.03 C m-2), consistent with our earlier 
report on graphene microelectrodes in buffer.142 The Faradaic current difference between 
the solutions of AfFtn and AfFtn-R (Figure 3.2c, Equation 3.3) can be explained using the 
above model. The best fit value for 𝐾 = 210 ± 60 mM derived from this model is in 
excellent agreement with the value obtained by liquid chromatography50 (𝐾 = 200 mM). 
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Exploring AfFtn Assembly on AuNP Surface 
To interrogate AfFtn assembly on AuNPs, we measured the real-time Faradaic 
charge transfer for solutions of AuNPs (𝐼AuNP, see Figure 3.4a), and of AuNP-ferritin 
assemblies based upon the wild-type ferritin AfFtn and a recently identified mutant, AfFtn-
AA (K150A/R151A), which features an octahedral arrangement of its subunits with 
“closed” (< 1 nm) pores.116 Representative data are shown in Figure 3.4b. When an AuNP 
is encapsulated in the closed-pore AfFtn-AA assembly, the AuNP surface should be less 
accessible compared to when AuNPs are encapsulated in AfFtn. The AfFtn-AA-containing 
sample should therefore have less charge transfer compared to AfFtn.  
 
Figure 3.4. Faradaic current and charge transfer for AuNP-containing samples. a) Faradaic current 
for AuNP as a function of ionic strength by graphene electrodes. The Faradaic current is negative 
and reaches its maximum magnitude for ionic strength ~240 mM due to competing effects of AuNP-
adsorption and ionic screening. b) Real-time charge transfer for AfFtn-AA-AuNP, AfFtn-AuNP, and 
AuNP measured by graphene electrodes. 
We used the Faradaic current of AfFtn-R as the baseline for assembled (24mer) 
ferritin, which leads to several strict requirements for accurate quantification of trans-pore 
current. First, ferritin must remain assembled with the AuNP enclosed. This is satisfied as 
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24mer assemblies of both AuNP-AfFtn and AuNP-AfFtn-AA are stable in the range of 
ionic strengths tested51 (40 – 340 mM). Second, all AuNPs must be encapsulated by ferritin 
with no free AuNPs in solution. As shown in Figure 3.5, more than 99% AuNPs were 
enclosed in a ferritin protein shell as confirmed by TEM and gel electrophoresis. We also 
verified that AuNPs were stable in the range of ionic strengths used without aggregation 
(Figure 3.6).  
 
Figure 3.5. Evidence of AuNP encapsulation. a) The TEM images for AfFtn-AuNP solution and 
AfFtn-AA-AuNP solution. The black dots are AuNPs. All the AuNPs are enclosed by a white, halo-
like ring, which corresponds to the protein shell. b) Native gel electrophoresis also confirms 
encapsulation. Gel was run at 100 V for 20 min. Overlapping red AuNP bands and blue protein 
bands (+stain gel) indicate encapsulation. 
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Figure 3.6. AuNP stability with varying ionic strength. Maximum of the surface plasmon resonance 
peaks measured for gold-nanoparticle PBS solutions with ionic strength ranging from 40 mM to 340 
mM. 
To quantify Faradaic current contributed by enclosed AuNPs, we calculated the 
difference between the current for AuNP-AfFtn (AuNP-AfFtn-AA), 𝐼AuNP-AfFtn 
(𝐼AuNP-AfFtn-AA) and the baseline (𝐼AfFtn-R): ∆𝐼=𝐼AuNP-AfFtn − 𝐼AfFtn-R (𝐼AuNP-AfFtn-AA −𝐼AfFtn-R), with results plotted in Fig. 3.7a. For AuNP-AfFtn, ∆𝐼 varied by ~0.12 pA through 
the range of ionic strength, with a minimum at ~240 mM. For AuNP-AfFtn-AA, ∆𝐼 was 
much smaller and essentially constant at -0.020 ± 0.005 pA. For AuNP-AfFtn, the plot of ∆𝐼 vs. 𝐼AuNP (Fig. 3.7b) followed a linear trend with slope a = 0.59 ± 0.05, suggesting that 
the efficiency of Faradaic charge transfer via AuNPs enclosed in open-pore AfFtn is ~60% 
of that for bare AuNPs. In contrast, for AuNP-AfFtn-AA, we found a slope a = 0.03 ± 0.03, 
suggesting that the presence of closed pores completely suppresses this charge transfer 
pathway. 
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Figure 3.7. Microelectrode can distinguish between closed and open pore AfFtn in presence of 
AuNPs. a) Difference in Faradaic current for solutions of AuNP-enclosed in A. fulgidus mutant 
ferritin K150A/R151A (AuNP-AfFtn-AA, blue triangles) and AuNP-enclosed in wild-type ferritin 
(AuNP-AfFtn, red squares) compared to the baseline current set by a solution of E65R ferritin 
(AfFtn-R). b) Faradaic current difference for AuNP-AfFtn-AA (blue triangles) and AuNP-AfFtn (red 
squares) as a function of the Faradaic current for AuNP. The lines are linear fits to the data. c) 
Charge-transfer efficiency 𝜉 as a function of ionic strength fitted by the formula for the model based 
on electrical double layer. 
This analysis suggests that the Faradaic current carried by the ferritin-AuNP system 
has two components: i) pore-mediated current via the AuNP and ii) current associated with 
the protein shell, quantified by 𝐼AfFtn-R. We define the trans-pore efficiency 𝜉 𝑐 =
a𝐼AuNP 𝑐 a𝐼AuNP 𝑐 + 𝐼AfFtn-R 𝑐  to quantify the fraction of the total current 
carried by the enclosed AuNPs. The efficiency increases monotonically by ~100% as the 
ionic strength increases from 40 mM to 340 mM (Figure 3.7c). In contrast to molecular 
diffusion through the pore, which is driven by a concentration gradient, the Faradaic current 
depends on the gradient of the electrostatic potential. Thus, negative charge at the edge of 
the AfFtn pores can suppress the (negative) Faradaic current via the enclosed AuNP over 
length scales given by the Debye screening length 𝜆D 𝑛𝑚 = 0.304 𝑐[𝑀]. Thus we 
expect that the efficiency will be affected by ionic strength approximately as 𝜉 =𝐴 4.5 − 𝑘𝜆D[nm] S where 𝐴 is a factor scaling area to efficiency, 4.5 nm is the pore 
diameter for AfFtn, and 𝑘 is ~ 1. The charge-transfer efficiency is well fit by this equation 
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(Fig. 3.3d) with best fit value 𝑘 = 1.2 ± 0.1. This experiment demonstrates the capability 
of graphene microelectrode measurements to differentiate between open- and close-pore 
structures in ferritin-nanoparticle assemblies, confirms the accessibility of enclosed 
AuNPs, and provides strong evidence that the AfFtn pore maintains a native-like structure 
in the presence of the enclosed AuNP.  
Conventional Catalysis Methods Comparison 
For confirmation and comparison, we used conventional catalysis methods to 
differentiate between wild-type AuNP-AfFtn and AuNP-AfFtn-AA: dehalogenation of a 
bisiodinated boron dipyrromethene derivative (I-BODIPY) and reduction of 4-nitrophenol. 
More AuNP surface area should be exposed in the AfFtn-containing sample compared to 
AfFtn-AA, and should therefore have greater AuNP catalytic activity. The reactions were 
monitored by different spectroscopic techniques: an increase in fluorescence at 507 nm 
was observed for the I-BODIPY dehalogenation reaction,149 and a decrease in absorbance 
at 400 nm was observed for the nitrophenol reduction.150  
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Figure 3.8. Catalysis assays distinguish between AfFtn and AfFtn-AA. a) Real-time fluorescence 
intensity of I-BODIPY dehalogenation catalyzed by AuNP-AfFtn-AA and AuNP-AfFtn solutions. b) 
Real-time UV-visible spectroscopy of reduction of 4-nitrophenol catalyzed by AuNP-AfFtn-AA and 
AuNP-AfFtn solutions. The solid curves are fits based on first-order kinetics. The corresponding 
catalytic reactions are shown in panels a-b. 
 
As shown in Figure 3.8a, the rate of increase in the fluorescence intensity in the 
AuNP-AfFtn solution (0.0081 ± 0.0002 A.U./min) is approximately 4 times larger than the 
AuNP-AfFtn-AA solution (0.0019 ± 0.0002 A.U./min). For the 4-nitrophenol reduction, 
AuNP-AfFtn had roughly twice the catalytic rate constant, k = (7.4 ± 0.7) x10-3 s-1 vs. (4.0 
± 0.3) x10-3 s-1 for AuNP-AfFtn-AA (Figure 3.8b). Neither ferritin contributed to the 
catalytic activity as shown in Figure 3.9.  
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Figure 3.9. Reduction of 4-nitrophenol in the presence of AfFtn (red) or AfFtn-AA (blue). Neither 
protein shows any change in A400, indicating no catalytic activity.  
For the catalytic assays, the difference in signal for AuNP-AfFtn versus AuNP-
AfFtn-AA is only four-fold and two-fold for the I-BODIPY and 4-nitrophenol reactions, 
respectively. In contrast, the difference between AuNP-AfFtn and AuNP-AfFtn-AA for the 
microelectrode is nearly 20-fold. Thus, our methodology based on graphene 
microelectrode is comparatively rapid (seconds versus tens of minutes), enables a 
quantitative estimate of the pore diameter through direct charge-transfer measurement 
through the protein shell, and overcomes limitations in sensitivity imposed by the AuNP 
catalytic reactions.  
3.3 Conclusions 
In summary, we have developed a graphene microelectrode device as a sensitive 
tool for structure-function analysis of AuNP-ferritin assemblies in solution. This all-
electronic method has multiple advantages for identifying protein pores compared to 
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conventional AuNP catalysis methods, and it provides a direct measurement of the pore-
mediated charge-transfer process. Our approach provides a way to explore protein structure 
at nm-scale and, more broadly, to explore interactions of biomolecules with inorganic 
nanomaterials in complex biofluids, systems shown to offer significant promise in bio-
imaging, sensing, catalysis and templated nanoparticle synthesis.  
3.4 Experimental Procedures 
Graphene growth. Copper foil (99.8% purity) was loaded into a four-inch quartz 
tube furnace and annealed for 30 min at 1050 °C in ultra-high-purity (99.999%) hydrogen 
atmosphere (flow rate 80 sccm; pressure 850mT at the tube outlet) for removal of oxide 
residues. Graphene was deposited by low-pressure chemical vapor deposition (CVD) using 
methane as a precursor (flow rate 45 sccm) at 1050 °C for 60 min.  
Graphene device fabrication. The graphene-copper growth substrate was coated 
with 500-nm layer of poly(methyl methacrylate) (PMMA, MicroChem), and the PMMA-
graphene film was floated off the surface by immersion in 0.1 M NaOH solution with the 
graphene-copper growth substrate connected to the cathode of a power supply. The 
PMMA-graphene film was transferred onto a 300 nm SiO2/Si wafer with an array of 5 
nm/40 nm Cr/Au contact electrodes that were previously fabricated using 
photolithography. Al2O3 (5 nm) was deposited on the whole wafer as a sacrificial layer, 
and 50 µm × 100 µm graphene microelectrodes were defined by photolithography with 
photoresist PMGI (MicroChem) and S1813 (MICROPOSIT) and oxygen plasma etching. 
The Al2O3 layer on top of the microelectrode areas was removed by the basic photoresist 
developer MIF-319 (MICROPOSIT). After removal of the photoresist residues with 1165 
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(MICROPOSIT), another passivation layer of photoresist SU-8 (MicroChem) was applied 
to the device, and the wells exposing the microelectrodes were defined via 
photolithography. 
Ferritin mutagenesis. The pAF0834 plasmid containing the AfFtn gene was 
provided by the laboratory of Dr. Eric Johnson at the California Institute of Technology. 
AfFtn-R was made by site-directed mutagenesis using the Stratagene QuikChange kit. The 
primers were obtained from Integrated DNA Technologies:  
sense (5ʹ-3ʹ) GATTTCGTTTCCCGTCGCGGTGGCCGTG 
antisense (5ʹ-3ʹ) CACGGCCACCGCGACGGGAAACGAAATC  
The mutated cDNA was transformed into XL1-Blue Supercompetent E. coli cells 
(Stratagene) according to the manufacturer’s protocol. The plasmid was isolated using a 
QIAprep Spin Miniprep kit (Qiagen). All sequencing was performed by the University of 
Pennsylvania DNA Sequencing Facility. The AfFtn-AA plasmid was purchased from 
DNA2.0 and transformed the same as AfFtn-R and wt AfFtn.  
Ferritin expression/purification. Production and purification of AfFtn and mutants 
was performed as previously published,52 with some modifications. The plasmid was 
transformed into BL21-Codon Plus(DE3)-RP competent E. coli cells (Stratagene) in TB 
medium (1 L containing 100 mg ampicillin, 35 mg chloramphenicol) at 37 °C with shaking 
at 225 rpm until OD600 ~0.8 was reached. The cells were induced with 1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG, Lab Scientific) and continued incubating for 4 h. Cells 
were centrifuged and frozen, followed by resuspension in buffer (20 mM phosphate, 20 
mM NaCl, pH 7.6) with an EDTA-free protease inhibitor cocktail tablet (ThermoFisher 
Scientific). Cell lysis was performed by treatment with lysozyme and sonication, followed 
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by nuclease treatment (15 min at room temperature, Pierce universal nuclease, 
ThermoFisher Scientific). The lysate was heat shocked to remove most endogenous E. coli 
proteins (10 min at 80 °C), buffer exchanged to induce ferritin assembly (2.5 M NaCl, 2 
mM EDTA, 20 mM phosphate, pH 7.6), and purified further using size exclusion 
chromatography (HiLoad 16/60 column, GE Healthcare). The purity of the protein was 
determined to be >95% by denaturing PAGE gel (4-15% Tris-HCl, Mini-Protean TGX 
gel), as seen in Figure 3.10. Protein concentration was determined using the Bio-Rad Protein 
Assay (based on the Bradford method), using bovine gamma globulin as the standard. 
Proteins were also characterized by MALDI-TOF-MS (Figure 3.11).  
 
Figure 3.10. Denaturing PAGE shows pure protein for all three samples, with monomer MW 
approximately 20 kDa, as expected.  
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Figure 3.11. MALDI-TOF-MS for all proteins. Measured mass for monomer (expected): AfFtn 
20315.3 (20316.1 Da), AfFtn-R 20347.8 (20343.1 Da), AfFtn-AA 20166.3 (20173.9 Da). Peaks at 
~40 kDa correspond to dimer. Sinapinic acid was used as a matrix, and linear-positive mode was 
used as the method.  
AfFtn solution and AfFtn-R solution preparation. Protein samples were prepared 
at 10 µM concentration in phosphate buffer (20 mM phosphate, pH 7.6), using NaCl to 
vary ionic strength (40, 90, 140, 190, 240, 340, 440, 540, 640 mM). To ensure accurate 
ionic strengths, samples were buffer exchanged on a Zebaspin column (ThermoFisher 
Scientific) equilibrated with the appropriate buffer. Samples were incubated overnight at 4 
°C to allow for equilibration. 
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AuNP-AfFtn solution and AuNP-AfFtn-AA solution preparation. Citrate-capped 
5 nm AuNPs were purchased from Ted Pella. The citrate was exchanged for bis(p-
sulfonatophenyl)phenylphosphine (BSPP, Strem Chemicals) as described previously.51 For 
device measurements, 1 mL samples were prepared at 0.3 mg/mL protein, 0.6 µM 5 nm 
AuNP-BSPP in 20 mM phosphate pH 7.6 and equilibrated at room temperature for 48 h 
with gentle agitation to ensure encapsulation. Protein NP samples were buffer-exchanged 
into various ionic strengths (40, 90, 140, 190, 240, 340 mM) using 10DG columns (Bio-
Rad) equilibrated with the appropriate phosphate buffer. The 10DG column also helped 
ensure that only encapsulated AuNPs remained in the samples, as confirmed by TEM and 
native gel electrophoresis (Figure 3.5). The first two fractions were combined, and AuNP 
concentration was verified by UV-vis spectroscopy. Because bare AuNPs cannot elute on 
a 10DG column, buffer exchange for the AuNP samples without protein was done using 
Zebaspin columns equilibrated at the same ionic strengths. All samples were diluted to 2 
mL to match the lowest concentration sample (20 nM). All samples were measured on the 
same device on the same day they were prepared, to minimize bulk AuNP aggregation.  
Preparation of I-BODIPY. I-BODIPY was prepared following the method of 
Zuber et al.151 A dark red solid product was obtained with a mass of 31.8 mg (69.7% yield). 
1H NMR (CD2Cl2): 7.54 (3H, m), 7.29-7.28 (2H, m), 2.62 (6H, s), 1.40 (6 H, s). Mass was 
verified using MALDI-TOF-MS with α-cyano-4-hydroxycinnamic acid (CHCA) as 
matrix. For characterization data, see Figure 3.12.  
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Figure 3.12. I-BODIPY characterization. a) 1H NMR spectrum of I-BODIPY in CD2Cl2. b) MALDI-
TOF-MS spectrum of I-BODIPY using CHCA as matrix. Peaks at 531.346, 650.073, 772.208, 
861.095, 1066.105 m/z correspond to matrix. Observed sample mass is 575.978, expected is 
575.954.  
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Fluorescence measurements. For the AuNP-catalyzed dehalogenation reaction, 10 
nM AuNP-AfFtn and 1 µM I-BODIPY were mixed in 50 mM HEPES buffer (pH 7.0). 
Steady-state fluorescence was monitored using a Varian Cary Eclipse fluorimeter, with 
PMT detector voltage at 800 V, excitation wavelength of 465 nm, and temperature of  
25 °C.  
4-Nitrophenol reduction. A solution of 5 nM AuNP-AfFtn and 50 µM 4-
nitrophenol (Fluka) was mixed in a cuvette. Freshly prepared aqueous NaBH4 (Fluka) was 
added to a final concentration of 2.5 mM and total sample volume of 1 mL. Absorbance at 
200—1100 nm was measured every 15 s at 25 °C using an Agilent 8453 UV-visible 
spectrometer. To determine the rate constant 𝑘, the data were fit to a first-order reaction, 
after subtracting the induction time (197 s): 
Abs = 𝜀 𝐴 A𝑒=T3 
where Abs is the measured absorbance, 𝜀 the extinction coefficient of 4-nitrophenol at 
400 nm (18000 M-1 cm-1), 𝐴 A the initial concentration of 4-nitrophenol (50 µM), and t 
the time. 
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CHAPTER 4: Controlling Gold Nanoparticle Seeded Growth in Thermophilic 
Ferritin Protein Templates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The content of this chapter has been submitted for publication. It has been adapted here: 
  
Reprinted with permission from Pulsipher, K.W.; Honig, S.; Deng, S.; Dmochowski, I.J. 
Controlling Gold Nanoparticle Seeded Growth in Thermophilic Ferritin Protein 
Templates. 2017. Submitted.  
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4.1 Introduction 
Ferritins are hollow, multimeric proteins whose native function is the oxidation, 
mineralization, and storage of iron.23 Because of their unique structure, ferritins can be 
used as mini-reactors to prepare inorganic nanoparticles (NPs) by reducing metal salts 
inside the protein cavity. In addition to iron, ferritins naturally bind other metals152–156 and 
can also be redesigned to enhance metal ion binding.48,108 Ferritin-templated NP synthesis 
can occur in room-temperature aqueous conditions, which is significantly more 
environmentally friendly compared to other conventional NP synthesis methods. 
Furthermore, protein-constrained growth offers potential advantages in controlling 
nanoparticle shape and size and can result in monodisperse samples. In 1991, Meldrum et 
al. presented the first examples of non-native inorganic NP synthesis inside ferritin, 
producing MnO2, FeS, and uranyl oxyhydroxide cores.157 Since that time, metallic cores of 
widely varying composition have been synthesized using ferritin, including 
semiconducting quantum dots,158–160 metal oxide NPs,161 noble metal NPs,103,108,162–164 and 
magnetic NPs.165–168 This wide range of protein-assisted reactions motivates the study of 
model ferritin systems, where the composition and presentation of polypeptides is well 
defined compared to many biologically controlled biomineralization reactions, e.g., the 
formation of shells and bone. 
While ferritin provides an excellent nanoreactor for the formation of NPs, it has 
been challenging to restrict particle growth to the interior of the protein cage. Many amino 
acids such as histidine and cysteine can bind metal ions, generating multiple nucleation 
sites on the interior and exterior ferritin surfaces. Zhang et al.163 demonstrated ferritin-aided 
AuNP growth on the surface of HSAF via reduction of HAuCl4– with either NaBH4 or 3-
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(N- morpholino)propanesulfonic acid (MOPS). Without HSAF present, synthesized 
AuNPs were unstable, demonstrating the improved passivation by ferritin. TEM showed 
the AuNPs to be on the exterior protein surface, with average diameters of 3.6 ± 1.2 and 
15.4 ± 4.5 nm for NaBH4 and MOPS, respectively.  
Ideally, NP formation should occur exclusively inside the ferritin cage, taking 
advantage of complete protein coating. Butts et al.108 mutated human H ferritin (HuHFtn) 
to encourage interior particle growth by removing all histidines and cysteines (four per 
subunit) present on the outer protein surface (called H4). A second protein mutant (H8) 
was made from H4 by adding four interior-surface cysteine residues per monomer to 
further promote NP growth in the central cavity. Ag NPs were formed by addition of 
AgNO3 in MOPS buffer, while illuminating with a 60 W bulb. To prepare AuNPs, AuCl3 
was added to ferritin in MOPS buffer, with formation of AuNPs complete in 1.5 h at room 
temperature. Samples were purified by centrifugation followed by desalting column to 
remove excess reagents and any large NPs growing outside ferritin. While wt, H4, and H8 
samples all showed characteristic yellow/brown color indicating formation of AgNPs, only 
H8 contained particles that remained stable and exhibited an AgNP SPR band through 
chromatography purification. H8 was also the only protein that formed stable, non-
aggregating AuNPs.  
Another approach to ensuring particle growth within the cavity is not through 
changes to ferritin itself, but in removing excess Au ions through desalting before 
reduction. Fan et al.169 demonstrated a two-step AuNP formation specifically inside HSAF. 
To generate small, uniform “seed” particles, HAuCl4 was incubated with HSAF for 3 h, 
then desalted with a sizing column to remove excess gold ions, particularly gold ions that 
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were weakly coordinated to the HSAF exterior surface. Strong reducing agent NaBH4 was 
then added to generate seed particles inside the HSAF cavity. After 3 h, additional HAuCl4 
and mild reducing agent ascorbic acid were added to further NP growth. After incubating 
overnight at room temperature, the solution was purified by size exclusion chromatography 
and ultracentrifugation through a sucrose gradient. The AuNPs were found to be 
exclusively within the protein cavity, had an average diameter of 6.3 ± 0.8 nm, and were 
mostly single crystalline.  
We have demonstrated a hybrid technique51 of encapsulating a 5-nm seed AuNP 
and performing in situ growth in the AfFtn cavity as shown in Figure 4.1. Addition of gold 
ions and reducing agent promoted AuNP growth. HAuCl4 was added to AfFtn and 
incubated at room temp for 3 h. The solution was desalted using a sizing column to remove 
excess AuCl4– and AfFtn surface-bound AuCl4–. Mild reducing agent ascorbic acid was 
added to reduce gold ions interacting with the AuNP surface. This process led to small, 
incremental growth. Two cycles led to AuNPs with an average diameter of 8.2 ± 1.9 nm, 
almost completely filling the ferritin cavity. Control experiments with AuNPs without 
protein present led to rapid precipitation, demonstrating the importance of the protein 
template in generating monodisperse, stable particles.  
	88 
	
 
Figure 4.1. Templated growth scheme for AuNPs encapsulated within AfFtn. After addition of gold 
ions, the sample is desalted to remove excess reagent and encourage growth inside the cavity. 
Mild reducing agent ascorbic acid reduces gold ions on the surface of the NP, growing the AuNP 
to fill the protein cage.  
 
AuNPs are most commonly prepared in ferritins using HAuCl4 or AuCl3 as the gold 
salt. Intrigued by the need for two rounds of seeded growth reaction in order to grow the 
AuNP to fill the AfFtn cavity, we decided to explore the role of the charge of the gold salt. 
Because the interior of AfFtn is negatively charged,50 we hypothesized that electrostatic 
repulsion was preventing HAuCl4 from entering the cavity in concentrations needed for 
significant particle growth. Shown in Figure 4.2, we used three gold salts with different 
charges in solution: HAuCl4, AuCl3, and Au(ethylenediamine)2Cl3. HAuCl4 deprotonates 
in aqueous solution to form a variety of anionic species in the form of [AuCl4-n(OH)n]-, 
where n = 0–4, depending on pH, chloride concentration, and oxidizing conditions.170 
AuCl3, which exists as Au2Cl6 in crystalline form,171 is initially neutral in solution. 
Electrospray ionization of aqueous gold(III) chloride produces a large variety of 
mononuclear clusters in the gas phase evidenced by mass spectrometry, e.g., 
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[AuCl2]+(H2O)n (n = 0-4), as well as dinuclear [Au2Cl5-xOHx]+(H2O)n (x = 0-1) species.172 
However, on the short timescale of our seeded growth reaction, the dimeric neutral Au2Cl6 
species likely predominates in aqueous buffer, pH 7.6. Finally, Au(en)2Cl3 loses its 
chloride counterions in water and has a +3 charge.173 
We also compared the templating capabilities of AfFtn with bovine serum albumin 
(BSA), which does not form an ordered cage around the AuNP and can directly adsorb to 
the AuNP surface.174 Previous studies using BSA to promote particle growth led to 
polydisperse Ag, Au, or Ag/Au alloy NPs.175–177 We therefore expected that BSA in seeded 
growth reactions would be unable to control AuNP growth to the same extent as AfFtn. 
Finally, we compared wt AfFtn templating with a double mutant AfFtn-AA 
(K150A/R151A)116 lacking the characteristic large pores, to determine whether the pores 
can facilitate molecular diffusion processes required for seeded nanoparticle growth.  
 
Figure 4.2. Predominant aqueous solution structures of gold complexes used. a) AuCl4– b) Au2Cl6 
c) Au(ethylenediamine)23+ 
 
4.2 Results and Discussion 
Effect of Gold Salt on Seeded Growth  
We synthesized Au(en)2Cl3 following the method of Zhu et al.173 and HAuCl4 and 
AuCl3 were used as received from Sigma Aldrich and Acros, respectively. We prepared 
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seeded growth samples following the procedure outlined in Figure 4.1, starting with pre-
encapsulated AuNPs with an average diameter of 6.0, 6.1, or 6.3 nm, as measured by TEM. 
The addition of 10,000 eq gold salt was expected to grow the starting ~6 nm AuNP to a 
diameter of just over 8 nm, assuming 100% incorporation of gold salt into the AuNP. The 
resulting samples were characterized by TEM and UV-visible spectroscopy. TEM 
micrographs (Figure 4.3) showed monodisperse particles with average diameters between 
6 and 8 nm for all AfFtn samples, with AuNPs from the AuCl3 sample most closely 
matching the AfFtn inner cavity diameter. We calculated a % yield based on the expected 
particle volume change with addition of 10,000 eq gold salt. The differences among the 
samples were striking: only 10% of the gold atoms were incorporated into AuNPs using 
HAuCl4, while 40% were incorporated using Au(en)2Cl3, and 70% for AuCl3. BSA-
templated samples were considerably more polydisperse, with somewhat larger particle 
diameters ranging from 7 to 9 nm. The larger particle “growth” is more likely due to 
particle aggregation, rather than greater deposition and reduction of gold ions. Some larger 
particles appeared by TEM to be slightly misshapen and resembled several conjoined 
particles, rather than single larger, spherical particles. Control experiments without either 
AfFtn or BSA present led to complete precipitation of the AuNPs for all Au ions tested, 
emphasizing the important role for protein stabilization.  
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Figure 4.3. TEM micrographs post-growth. a) Representative AfFtn-AuNP micrographs. b) 
Representative BSA-AuNP micrographs. All scale bars are 50 nm. c) TEM size distributions for 
AfFtn-AuNP pre- (blue) and post- (red) growth. d) TEM size distributions for BSA-AuNP pre-(blue) 
and post- (red) growth. AfFtn-AuNP particles are highly monodisperse post-growth, while BSA-
AuNP samples are less so, due to the lack of protein templating. 
Because TEM is not an ensemble measurement and can be prone to bias, we also 
characterized the bulk solution samples by UV-visible spectroscopy. Due to the optical 
properties of the AuNPs, a surface plasmon resonance (SPR) peak is observed in the UV-
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vis spectrum. The monodispersity of the sample is reflected in the width of the SPR peak, 
with more monodisperse samples showing a narrower peak. We compared the UV-vis 
spectra of the samples pre- and post-growth, as shown in Figure 4.4 and summarized in 
Table 4.1. Supporting the TEM results, all of the AfFtn samples showed a narrowing of the 
SPR peak post-growth, with AuCl3 showing the greatest change (-14 nm). In contrast, the 
BSA control samples ranged from marginal narrowing (-4 nm, HAuCl4) to significant 
broadening (+30 nm, AuCl3). With lower monodispersity than the AfFtn-templated 
samples, the BSA samples demonstrate the requirement for ordered protein assembly 
around the AuNP surface to ensure controlled particle growth, i.e., protein templating. 
 
Figure 4.4 UV-vis spectra pre-growth (blue) and post-growth (red). a) AfFtn-AuNP samples. b) 
BSA-AuNP samples. A narrowing of the surface plasmon resonance peak at ~520 nm indicates 
more monodisperse sample.  
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Table 4.1. Summary of UV-vis and TEM results 
Sample Davg (nm)
a Nb Δ2xHWHM (nm)c ΔDavg (nm)d 
AfFtn HAuCl4 6.3 ± 1.1 1262 -8 0.3 
AfFtn AuCl3  7.8 ± 0.9 508 -14 1.5 
AfFtn Au(en)2Cl3 7.0 ± 0.8 648 -6 1.0 
BSA HAuCl4 7.1 ± 0.9 520 -4 0.8 
BSA AuCl3  9.4 ± 3.7 530 +30 3.3 
BSA Au(en)2Cl3 8.0 ± 2.8 358 +14 1.9 
 
aDavg is average diameter calculated after using Analyze Particles function in ImageJ111 to measure particle 
areas. 
bNumber of particles used to calculate average diameter.  
cThe change in twice the half-width at half-max (HWHM) gives a measure of the peak width, which is 
reflective of sample monodispersity.  
dBatches varied slightly, with average initial particle diameters of either 6.0, 6.1, or 6.3 nm.  
 
It is striking that the seeded growth experiments with AfFtn and BSA showed the 
same gold salt preference, with the largest AuNPs formed with AuCl3, followed by 
Au(en)23+ and AuCl4– (Table 4.1). Similar to AfFtn, BSA is an acidic protein, with 
estimated pI of 4.7. Thus, both proteins at pH 7.6 should electrostatically repel AuCl4–, 
leading to less efficient AuNP growth. Moreover, the electrostatic interaction of the gold 
salt with the negatively charged, BSPP-coated AuNP should also disfavor AuCl4–. 
However, the preference for AuCl3 over Au(en)23+ likely arises from the much lower 
reduction potential of Au(en)2Cl3, which was reported to be -0.290 V and disfavors 
reduction by ascorbate.173 The standard reduction potential for Au(III) chloride species is 
typically much more favorable, as shown by this half-reaction:  
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AuCl4- + 3e- à Au + 4 Cl-    E° = 1.0 V vs. NHE.178,179 Our results demonstrate the 
significant effect of the charge and reduction potential of the gold complex on seeded 
particle growth within AfFtn.  
The AfFtn AuCl3 post-growth sample was further analyzed by native gel 
electrophoresis (Figure 4.5). By native gel, AfFtn and the templated AuNPs remained 
associated, with overlapping blue protein and red NP bands. Combined with TEM and UV-
vis data, this suggests that the AuNP remains within the AfFtn cavity and no formation of 
de novo particles occurs. The size exclusion chromatography (SEC) FPLC trace shows 
several peaks, which can be assigned to AfFtn 24mer (presumably with AuNP inside) and 
excess ascorbic acid (Figure 4.6a). Circular dichroism spectroscopy was used on the 
collected fractions to verify these assignments (Figure 4.6b). However, the sample 
concentration was low and the S:N was poor, making it difficult to discern whether any a-
helix signal was present in the “24mer” peak. The spectrum for the ascorbic acid peak was 
more distinct and could be confidently assigned based on a published spectrum.180 None of 
the fractions collected appeared red in color, but a faint thin red band was noted at the top 
of the column. Even though the AuNPs appear to be encapsulated within the AfFtn cavity, 
they do not appear to be passing through the filter at the top of the column successfully. 
Whether this is due to some non-ideal interaction with the filter material or the general 
conditions of the SEC experiment (high pressure flow) remains to be determined.  
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Figure 4.5. Native gel electrophoresis of AfFtn AuNP post-seeded growth using AuCl3 as the gold 
salt. Overlapping red AuNP and blue protein bands indicate particles remained inside the ferritin 
cage. 
 
 
Figure 4.6. a) Size exclusion chromatography of AfFtn AuNP post-seeded growth using AuCl3 as 
the gold salt. Peak at ~10 mL is expected to correspond to grown AuNP encapsulated within AfFtn, 
~16 mL AfFtn dimer (cage disassembly product), ~24 mL excess ascorbic acid. b) Circular 
dichroism spectroscopy analysis of SEC fractions. S:N is low for all samples, making it difficult to 
identify any characteristic a-helix signal, though fraction 16 does resemble the published spectrum 
of ascorbic acid.  
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To better understand the seeded growth process using AuCl3, we collected a UV-
visible spectrum after each step (Figure 4.7). After addition of AuCl3, the solution 
immediately turned more purple in color but remained clear. The UV-vis spectrum shows 
a corresponding red shift of 18 nm (from 522 to 540 nm) in the SPR peak. After incubation 
for 3 h at rt and desalting the sample, the peak remained red-shifted but showed a slight 
narrowing on the right side, indicating the removal of larger AuNP aggregates. TEM results 
suggest this red shift is due to deposition of gold ions on the AuNP surface and clustering 
of multiple AfFtn-AuNP particles. Post-desalting we measured an increase in average 
AuNP diameter of 0.4 nm (Figure 4.8a), corresponding to a monolayer of gold ions,181 as 
seen in the templating scheme in Figure 4.1. By TEM we also observed AfFtn-AuNP 
clustering (Figure 4.8b). Although the grid was unstained, the outlines of AfFtn donut-like 
shapes are clearly visible, likely due to electron-dense gold ions decorating their surfaces 
and interior cavities. After addition of ascorbic acid, the SPR peak immediately blue-
shifted to 523 nm (Figure 4.7), and the final particle size was reached. TEM samples 
prepared immediately after ascorbic acid addition and after 24 h looked very similar 
(Figure 4.9), indicating rapid AuNP growth. Because the growth happens so rapidly, most 
of the gold ions necessary for increasing the particle size must be within the cavity or on 
the AuNP surface by the end of the 3 h incubation with gold salt, which is also consistent 
with the TEM data (Figure 4.8a). 
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Figure 4.7. UV-visible spectra after each step in the seeded growth process. A large red-shift is 
seen after the addition of AuCl3, along with SPR broadening. Desalting narrows the SPR somewhat. 
Addition of ascorbic acid results in a blue-shift almost to the initial wavelength, along with SPR 
narrowing.  
 
Figure 4.8 TEM analysis after AuCl3 addition. a) TEM micrograph after 3 h incubation with AuCl3 
showing particle size increase of 0.4 nm due to gold ion deposition. 241 particles were measured 
for the pre-growth sample and 338 particles were measured for the +AuCl3 sample. b) Evidence 
for clustering of AfFtn-AuNPs after addition of AuCl3. Scale bars are 100 nm for both images.  
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Figure 4.9. TEM micrographs of samples post-addition of ascorbic acid, comparing immediate and 
24 h time points. Particle size was measured using ImageJ, 111 with 5-infinity nm2 as the size range 
and 0.5-1.0 as the circularity. 338 particles were analyzed for 0 h sample, 330 for 24 h.  
Effect of ferritin pore size on templating 
Finally, we were interested in comparing the templating capabilities using AuCl3 
of AfFtn-wt with a closed pore mutant AfFtn-AA (K150A/R151A).116 We have recently 
shown that wt and closed pore AfFtn maintain their quaternary structure upon 
encapsulation of AuNP, with the open pore preserved for wt (see Chapter 3). The large (4.5 
nm) open pore of wt should facilitate easy access to the AuNP surface for gold ions in 
solution, while gold ions added to the AfFtn-AA sample will need to diffuse through much 
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smaller (< 1 nm) openings between subunits in the assembled protein, or rely upon dynamic 
protein structural fluctuations.  
We repeated the same seeded growth protein-templating reaction with AfFtn-AA 
and characterized the post-growth sample by UV-vis spectroscopy and TEM (Figure 4.10). 
The post-growth average particle size was 7.0 ± 0.9 nm, corresponding to 40% yield, as 
determined by TEM (151 particles measured). The UV-vis spectrum showed a change in 
SPR width of -10 nm, indicating narrowed sample size distribution. Our results indicate 
that AfFtn-AA templates monodisperse particle growth, but to a smaller final diameter 
compared to wt. This may be due to less AuCl3 present in the cavity when the reducing 
agent is added. Bulky 5,5′-dithiobis-2-nitrobenzoic acid was recently shown to diffuse 
more slowly into the internal cavity of AfFtn-AA, compared to AfFtn-wt,182 suggesting the 
3 h incubation period used in our reaction is not long enough for cavity saturation. Several 
closed-pore ferritins have been shown to template AuNP growth, although the final particle 
size is generally smaller than the internal cavity diameter.108,169,183 With a resulting 
diameter of 7.8 ± 0.9 nm, our seeded growth method using AuCl3 and wt AfFtn shows 
large AuNPs formed within ferritin (compared to 6.3 ± 0.8 nm in HSAF,169 2-4 nm in 
human H ferritin,108 and 5.7 ± 1.6 nm in HSAF183). Although the final particle size is 
slightly smaller than our original iterative templating process (8.2 ± 1.9 nm),51 seeded 
growth using AuCl3 as presented here is considerably more efficient and twice as fast, 
requiring only one addition of gold ions and reducing agent, instead of two. In addition, 
the particles formed using a single round of AuCl3 addition are more monodisperse, as 
measured by both TEM (0.9 nm average diameter standard deviation versus 1.9 nm) and 
UV-vis (narrowing of SPR versus slight broadening).  
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Figure 4.10. Characterization of AfFtn-AA AuNP templated growth. a) TEM micrograph of post-
growth sample. Scale bar is 100 nm. b) UV-vis spectrum of pre-growth (blue) and post-growth (red) 
samples.  
 
Recently published crystal structures of recombinant horse liver ferritin (rHLFr) in 
the presence of gold ions and reducing agent shed light on how gold ions might interact 
with the ferritin cavity.184 rHLFr has octahedral symmetry, with similar assembly to the 
closed pore AfFtn-AA. Au ions were found to coordinate in three locations in rHLFr: at 
the 3-fold axis, at an engineered accumulation center diagonal from the 3-fold axis 
containing two additional cysteines, and at a Met and His pair across from the accumulation 
site. After addition of NaBH4 reducing agent, the gold ions migrated to the 3-fold axis and 
formed a sub-nanocluster. While AfFtn lacks cysteine and methionine residues (apart from 
the start Met, which may be cleaved during production in E. coli), several gold-binding 
amino acids185 decorate the 3-fold axis (Figure 4.11a). These amino acids may bind gold 
and direct its entry into the cavity and to the AuNP surface for both open and closed pore 
AfFtn. The large triangular pore of AfFtn is also rimmed with gold-binding amino acids 
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(Arg, His, Tyr, Lys, see Figure 4.11b). These features, combined with its open accessibility 
for easy diffusion, may help to improve Au loading over AfFtn-AA.  
 
Figure 4.11. Locations of gold-binding amino acids along the pores of AfFtn. a) Small 3-fold pores 
feature Tyr119, His104, and Lys114, all of which have been shown to have an affinity for Au ions. 
b) The large triangular pore is also lined with gold-binding amino acids including Arg, His, Tyr, Lys.  
4.3 Conclusions 
The selection of gold salt is an important consideration for optimizing AfFtn-
templated AuNP seeded growth. Neutral AuCl3 yielded larger AuNP that filled the AfFtn 
cavity more completely compared to charge repulsive AuCl4- or charge complementary 
Au(en)2Cl3 (70% gold atom incorporation versus 10% and 40%), which also led to greater 
AuNP monodispersity. The lack of an open pore in the mutant AfFtn-AA inhibits AuNP 
growth, showing the advantage of a ferritin template with a more porous cage structure. 
The AuNP synthetic process described here strikes a favorable balance between high gold 
incorporation efficiency and large particle size compared to all other ferritin-AuNP 
synthetic routes described to date. The porous protein coverage of AfFtn provides an 
elegant way to control AuNP chemistry in solution, preventing AuNP aggregation and bulk 
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precipitation. Such a functional, symmetric structure is difficult to recreate in abiological 
synthetic systems, e.g., by coating with polymer or small molecule ligands. AfFtn-AuNP 
conjugates could be used as more selective catalysts or for further NP manipulation, such 
as templating further NP growth or surface functionalization through the AfFtn open pores.  
4.4 Experimental Procedures 
 Protein expression and purification. Thermophilic ferritin protein was expressed 
and purified as previously published52 (see Chapter 2). The pAF0834 plasmid containing 
thermophilic ferritin was obtained from Eric Johnson (California Institute of Technology) 
and the plasmid containing K150A/R151A was purchased from DNA 2.0 (now ATUM). 
Purity was confirmed using SDS-PAGE (4–15% Tris–HCl, Mini-Protean TGX gel), shown 
in Figure 4.12. Protein concentration was determined using the Bradford Assay, with 
bovine gamma globulin as a standard. 
	
Figure 4.12. SDS-PAGE of AfFtn and AfFtn-AA used, confirming purity with bands at ~20 kDa, 
corresponding to monomer weight. 
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Gold nanoparticle ligand exchange. Citrate-coated 5 nm AuNPs were purchased 
from TedPella. Actual average diameter when measured by TEM was 6.0-6.3 nm, see 
Figure 4.13. Ligand exchange from citrate to bis-p(sulfonatophenyl)phenylphosphine 
(BSPP) was done following previously published procedure.51 Briefly, 50 mL of AuNP 
solution was stirred overnight with 20 mg BSPP at rt. NaCl was added until the NPs 
precipitated, the sample was centrifuged at 3000 rpm, 4 °C for 30 min. The supernatant 
was discarded and the AuNP pellet was resuspended in DI H2O and reprecipitated with 
methanol. The sample was then centrifuged again at 3000 rpm, 4 °C for 30 min. The 
washed pellet was resuspended in DI H2O and the AuNP concentration was measured using 
an extinction coefficient provided by the manufacturer of 9.696 x 106 M-1 cm-1 at 520 nm. 
	
Figure 4.13. Transmission electron microscopy of citrate-coated AuNPs. TEM sample was 
prepared on a carbon-coated copper grid without stain, and imaged using a Tecnai T-12 
microscope operating at 120 keV. Particle size was measured using the Analyze Particles function 
on ImageJ,111 with 5-infinity nm2 as the size range and 0.5-1.0 as the circularity. Scale bar is 100 
nm. For batch shown, the average particle diameter was 6.0 ± 0.8 nm, based on measurement of 
337 particles. 
AfFtn-AuNP encapsulation. Protein-AuNP samples were prepared by first 
disassembling AfFtn overnight in 20 mM phos (pH 7.6) buffer at 4 °C. Disassembled 
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protein was mixed with AuNPs to a final concentration of 0.6 µM AfFtn, 0.6 µM AuNP in 
20 mM phos (pH 7.6) buffer. The sample was incubated at room temperature with gentle 
agitation (gel rocker) for 48 h.  
Synthesis and characterization of Au(en)2Cl3. Au(en)2Cl3 was prepared following 
the method of Zhu et al.173 HAuCl4 (0.50 g, 1.5 mmol) was added to 5 mL H2O, followed 
by dropwise addition of 0.225 mL (3.4 mmol) ethylenediamine with stirring. The red-
orange solution was stirred for 30 min at rt. The product was precipitated with 35 mL 
ethanol and then vacuum filtered (washing with ethanol). The resulting pale yellow solid 
was dried overnight under vacuum and isolated in 47% yield (290 mg, 0.92 mmol). The 1H 
NMR spectrum in D2O had one peak corresponding to the amine hydrogens at 3.291 ppm 
(Figure 4.14a). The product was also characterized by elemental analysis: Found %: C, 
11.19; H, 2.94; N, 13.42; Cl, 24.97. Calc %: C, 11.34; H, 3.81; N, 13.23; Cl, 25.11. For 
further confirmation of the identity of the product, cyclic voltammetry was performed using 
Ag/AgCl as reference electrode, glassy carbon as working electrode, and Pt as counter 
electrode (Figure 4.14b). The electrolyte solution was 0.4 M KCl and the scan speed was 
0.1 V/s.  
	105 
	
 
Figure 4.14. Characterization of Au(en)2Cl3. a) NMR spectrum of Au(en)2Cl3, taken in D2O. Peak 
at 3.291 ppm corresponds to published NMR spectrum.186 b) Cyclic voltammetry of Au(en)2Cl3, 
matching data previously by Zhu et al.186. 
Gold atom stoichiometry calculation. The theoretical number of gold atoms 
needed to grow particle size from 6 nm to 8 nm was based on the unit cell volume of gold. 
Gold crystallizes in fcc packing, resulting in 4 atoms per unit cell. The volume of a unit 
cell of gold is 0.0679 nm3. Using 𝑉 = VW 𝜋𝑟W, the volume of a 6 nm AuNP is 113.097 nm3 
and the volume of an 8 nm AuNP is 268.083 nm3; therefore, an additional volume of 
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154.985 nm3 is needed. If there are 4 gold atoms for every 0.0679 nm3, 9130 gold atoms 
will be needed to increase the particle size to 8 nm. 
Seeded growth templating. AfFtn-AuNP sample (500 µL of 0.6 µM solution) was 
used for the templated growth. 10,000 eq of gold salt were added (from 0.1 M stock 
solution) and the sample was incubated at rt for 3 h. Excess gold ions were then removed 
using a 10DG gel filtration column (Bio-Rad), equilibrated with 20 mM phos pH 7.6 buffer. 
Four 1 mL fractions were collected and those containing protein and AuNP (as confirmed 
by UV-vis spectroscopy) were combined. Ascorbic acid (30,000 eq from 0.1 M freshly 
prepared stock) was added, and the sample incubated overnight at rt.  
Seeded growth AuNP characterization. UV-vis spectra were collected on an 
Agilent 8453 UV-visible spectrometer. Samples for transmission electron microscopy 
(TEM) were prepared on carbon-coated copper grids (Electron Microscopy Sciences), 
unstained. Grids were imaged on a Tecnai T-12 microscope operating at 120 keV. Particle 
diameters were calculated after measuring particle area using the Analyze Particles 
function on ImageJ 111, with 5-infinity nm2 as the size range and 0.5-1.0 as the circularity. 
At least 150 particles were analyzed per sample. Native agarose gels (0.7%) were run at 
100 V, 20 min, rt. Circular dichroism spectroscopy was done using an Aviv 410 CD 
spectrometer with 1 mm quartz cuvettes, scanning 190-260 nm at 25 °C. Size exclusion 
chromatography was done on a Superdex200 Increase 10/300 GL column on an AKTA 
FPLC system, using 20 mM phos (pH 7.6) as the buffer. 200 µL of AfFtn-AuNP sample 
was injected onto the column and eluted at 0.9 mL/min. 
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CHAPTER 5: THERMOPHILIC FERRITIN ENCAPSULATION OF 
SUPERCHARGED GFP 
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5.1 Introduction  
Supramolecular host-guest complexes have wide-ranging applications including 
sensing,187,188 catalysis,189 separations,190 and drug delivery.191 Synthetic host-guest 
systems include cyclodextrin-adamantyl-functionalized molecules, which have been used 
in delivery of nucleic acids191,192 and chemotherapeutics,193 and cyclodextrin-azobenzene 
host-guest pairs, which have been used for glucose sensing.188 Cucurbituril-guest 
interactions have been used in catalyzing 1,3-dipolar cycloadditions, and oxidation, 
hydrolysis, and photochemical reactions.194 The affinity of calixarenes for many amino 
acids has been leveraged to make protein microarrays for biosensing.195 In nature, host-
guest complexes are often seen in the form of protein-protein interactions. Chaperone 
proteins are one example, where a host protein accepts a guest protein, helping it to fold or 
refold properly.196 Likewise, in bacterial microcompartments polyhedral protein shells 
encapsulate an enzyme, preventing the release of toxic metabolic intermediates.197 Several 
non-native protein-protein host-guest complexes have been reported using lumazine 
synthase from Aquifex aeolicus, encapsulin, or viral capsids such as MS2, cowpea chlorotic 
mottle virus (CCMV), and P22. These large (>25 nm diameter) protein cages have been 
shown to effectively encapsulate fluorescent protein variants,10,11,198,199 HIV protease,8 
Cas9,200 E. coli alkaline phosphatase,198 and a variety of other enzymes with wide ranging 
structures and functions.9 Encapsulation of a guest protein within a host protein has enabled 
kinetic studies of enzymes in confined spaces,201,202 as well as the development of confined 
enzyme cascades.203 Protein host-guest complexes have also been engineered to more 
easily crystallize a guest protein.204 
	110 
	
Shown in Figure 5.1, we report a protein-based host-guest complex featuring 
thermophilic ferritin from Archaeoglobus fulgidus (AfFtn) and a supercharged variant of 
green fluorescent protein with a theoretical net charge of +36 (GFP(+36)).205 AfFtn exists 
as dimers of four-helix bundles at low ionic strength (< 200 mM NaCl). Self-assembly of 
12 dimers occurs in high ionic strength buffer to form a hollow, cage-like 24mer with 
tetrahedral symmetry and four large (4.5 nm), triangular pores.49 Cargo smaller than the 
24mer inner diameter (8 nm) can be encapsulated within the protein interior. We have 
demonstrated the encapsulation of 6-nm gold nanoparticles, where the particles nucleate 
assembly via their high surface charge.50–52 We hypothesized that highly charged 
macromolecules of appropriate size could be encapsulated in a similar process. Here, we 
show that AfFtn and mutants with altered assembly properties can encapsulate GFP(+36) 
in a rapid, stoichiometric manner, maintaining the native characteristics of both proteins. 
An AfFtn mutant lacking the salt-dependent assembly and large triangular pores was able 
to encapsulate GFP(+36), indicating that cage dynamics play a role in assembly. Notably, 
wildtype GFP was not encapsulated by AfFtn, highlighting the important electrostatic 
nature of the interaction. Unlike prior protein-protein host-guest examples where extensive 
directed evolution,8 addition of osmolyte,198 change in pH,201 or covalent attachment199 was 
needed, our system requires no added reagents other than the proteins themselves and 
works well for wt AfFtn. We demonstrate the ability to tune AfFtn-GFP(+36) 
encapsulation efficiency using AfFtn mutants with different assembly characteristics. 
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Figure 5.1. Encapsulation of GFP(+36) by wt-AfFtn (top) and E65R-AfFtn (bottom). For wt, 12 
AfFtn dimers self-assemble around positively charged GFP(+36) to form a 1:1 AfFtn 
24mer:GFP(+36) host-guest complex. E65R encapsulates a single GFP(+36) starting with a 
complete cage. 
5.2 Results and Discussion 
 AfFtn and GFP(+36) were mixed in varying stoichiometries (AfFtn 
24mer:GFP(+36)) ranging from 1:3 to 3:1 in low ionic strength buffer (20 mM phos, pH 
7.6) and analyzed by native gel electrophoresis (Figure 5.2a). A single fluorescent green 
band can be seen running toward the positive gel terminal, corresponding to the AfFtn-
GFP(+36) complex. With GFP(+36) in excess, a green band running toward the negative 
terminal appears as free GFP(+36). Size exclusion chromatography (SEC) was used to 
verify encapsulation (Figure 5.2b). A280 was monitored during chromatography, while 
GFP(+36) fluorescence was measured for each fraction afterward using a microplate 
reader. The main A280 peak corresponded to AfFtn 24mer elution volume and overlapped 
with the I509 GFP(+36) fluorescence peak, indicating encapsulation. The encapsulation 
product fractions were combined, concentrated, and analyzed by dynamic light scattering 
	112 
	
(DLS) to verify AfFtn assembly (Figure 5.2c). The measured average particle diameter 
matched that of AfFtn 24mer at 13.9 nm, suggesting that GFP(+36) is inside AfFtn, rather 
than adsorbed to its surface, or forming a non-specific, unordered aggregate with multiple 
AfFtn dimers. GFP(+36) absorbance and emission spectra collected pre- and post-
encapsulation were highly similar, indicating the protein remained folded (Figure 5.3).  
 
Figure 5.2. Encapsulation of GFP(+36) by AfFtn. a) Native gel electrophoresis varying 
stoichiometry AfFtn 24mer:GFP(+36). GFP(+36) forms a complex with AfFtn at a ratio of 1:1, with 
excess GFP(+36) running toward the negative gel terminal due to its higher positive charge. b) Size 
exclusion chromatography of AfFtn-GFP(+36) complex, monitored by absorbance at 280 nm 
(yellow) and fluorescence at 509 nm (green). Peak at 12.5 mL corresponds to AfFtn-GFP(+36), 
peak at 17.5 mL corresponds to AfFtn dimer. c) Dynamic light scattering volume size distribution of 
SEC peak at 12.5 mL. Average diameter is 13.9 nm with a PDI of 0.256.  
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Figure 5.3. Optical properties of GFP(+36) pre- and post-encapsulation. a) Absorbance spectrum 
with and without AfFtn. b) Fluorescence spectrum with and without AfFtn. 
 
 As another confirmation of encapsulation, we incubated AfFtn-GFP(+36) with 
nickel nitrilotriacetic acid (Ni-NTA) agarose resin. GFP(+36) has a histidine-tag for 
purification purposes and will therefore bind strongly to the nickel-laced resin. 
Dissociation from the resin is triggered by addition of imidazole, which competes off the 
bound protein. If GFP(+36) is encapsulated within a ferritin cage, however, the His-tag 
should be less able to bind to the Ni-NTA resin. After incubating AfFtn with GFP(+36) 
overnight and purifying by SEC, we mixed the sample with a Ni-NTA slurry. As a control, 
we also incubated GFP(+36) alone with the resin. After an hour of binding time, we 
centrifuged the samples to separate the resin and removed the supernatant. We washed the 
resin with buffer three times, each time centrifuging the sample and removing the 
supernatant. We then added buffer with 250 mM imidazole to remove any bound protein 
and repeated the centrifuging/supernatant removal three times. We measured fluorescence 
at 509 nm for all supernatant samples (Figure 5.4). Significant GFP(+36) fluorescence is 
seen for the load AfFtn-containing sample, indicating that little GFP(+36) bound to the 
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resin. In contrast, low fluorescence was seen for the GFP(+36) load sample (no AfFtn) and 
significant fluorescence was seen for the first elution sample, indicating that the majority 
of the protein bound to the resin and was eluted using imidazole. Thus, the majority of 
GFP(+36) appears to be encapsulated within AfFtn.  
 
Figure 5.4. Ni-NTA assay shows lack of GFP(+36) binding to resin after encapsulation within AfFtn. 
  
 Having confirmed GFP(+36) encapsulation by AfFtn, we were interested in the 
kinetics of the encapsulation process. Shown in Figure 5.5, we used native gel 
electrophoresis and SEC to analyze 1:1 AfFtn 24mer:GFP(+36) samples incubated for 
varying time points. Based on both methods, encapsulation occurs almost immediately, 
with a fluorescent band corresponding to AfFtn-GFP(+36) at 0 h, and ~60% assembled 
AfFtn with GFP(+36) fluorescence at ~30 min (measurement time).  
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Figure 5.5. Kinetics of GFP(+36) encapsulation. a) Native gel time course for GFP(+36) 
encapsulation by AfFtn. Fluorescent band that appears within the analysis time corresponds to 
encapsulation product. b) Size exclusion chromatograms show fast overlap of GFP(+36) 
fluorescence (green) and A280 peak corresponding to AfFtn 24mer (yellow).  
 
We previously reported three AfFtn mutants with varying self-assembly properties: 
A127R, D138K, and E65R (see Chapter 2). We were interested in exploring whether they 
could successfully encapsulate GFP(+36) in a similar fashion as wt. Shown in Figure 5.6, 
we see evidence of encapsulation for all AfFtn mutants by native gel. However, for A127R 
and D138K there are two clear AfFtn bands seen in the Coomassie-stained gels, one of 
which overlaps with GFP(+36) fluorescence. This is presumably the encapsulation product, 
while the second band appears to be unassembled AfFtn dimer, as it increases in intensity 
when AfFtn is in excess. At 1:1 AfFtn 24mer:GFP(+36), D138K has more encapsulation 
product compared to A127R, which is consistent with its more favorable assembly. It is 
striking that E65R is able to efficiently encapsulate GFP(+36), given its propensity to 
remain assembled, and to assemble in a closed-pore conformation. This also differs from 
previous experiments with gold nanoparticles (AuNPs), which demonstrated a lack of 
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encapsulation (see Chapter 2). Encapsulation of large protein cargo without disassembling 
into small subunits is not without precedent, however. Lumazine synthase from Aquifex 
aeolicus was found to encapsulate supercharged ferritin starting from assembled capsids 
or capsid subunits, albeit with lower yields for assembled capsids.118 The cage dynamics 
are such that protein cargo significantly larger than the 4-nm pores206 can still enter the 
cavity. Similar dynamics may be at play for E65R, enabling the GFP(+36) encapsulation 
observed. GFP(+36) is also smaller than a 6-nm AuNP and potentially more flexible, 
compared to the hard, inorganic AuNP surface. These factors may help facilitate entry into 
the E65R cavity for GFP(+36), compared to an AuNP. 
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Figure 5.6. Native gel electrophoresis for mutant AfFtn-GFP(+36) samples with varying 
stoichiometries.  
 
Mutant AfFtn-GFP(+36) samples were also analyzed by SEC and transmission 
electron microscopy (TEM). GFP(+36) fluorescence was observed mostly in SEC peaks 
corresponding to AfFtn 24mer, indicating successful encapsulation for all mutants (Figure 
5.7), with varying assembly yields. A127R, which had previously been shown to disfavor 
assembly compared to wt (Chapter 2), had less AfFtn 24mer present compared to D138K 
and E65R (Table 5.1). These yields do not necessarily represent encapsulation yields, as 
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E65R and D138K will have some proportion of protein that runs as a 24mer, whether a 
cargo protein is present. The patterns previously observed in ferritin self-assembly are also 
seen for self-assembly in the presence of GFP(+36). SEC fractions containing the highest 
GFP(+36) fluorescence were further analyzed by TEM. As seen in Figure 5.8, ferritin 
donut-like shapes are observed for all samples including wt, further suggesting the AfFtn 
variants assembled with GFP(+36) inside.  
 
Figure 5.7. Size exclusion chromatography of mutant AfFtn-GFP(+36). Absorbance at 280 nm was 
measured during the experiment (yellow), and fluorescence intensity at 509 nm was measured 
post-SEC using a microplate reader (green).  
 
Table 5.1. Size exclusion chromatography of AfFtn GFP(+36)  
 
 
Sample % 24mer 
wt GFP(+36) 65.2 
A127R GFP(+36) 19.9 
D138K GFP(+36) 76.1 
E65R GFP(+36) 87.9 
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Figure 5.8. Transmission electron microscopy of 24mer fractions from SEC. Scale bars are 100 
nm for all images.  
By measuring UV-vis spectra, we were able to calculate the number of GFP(+36) 
per AfFtn 24mer. For AfFtn wt, there are an average of 1.8 GFP(+36) per 24mer. A127R 
had an average of 1.5, while D138K and E65R had 0.5. GFP loading levels of 0.5-1.8 fall 
in the expected range, considering the cavity volume of AfFtn is approximately 270 nm3 
based on an internal diameter of 8 nm, while the volume of a single cylindrical GFP(+36) 
molecule (3-nm diameter x 4-nm height)118 is approximately 33 nm3, giving a theoretical 
maximum of 8 GFP(+36) per 24mer. The high charge of GFP(+36) likely disfavors close 
packing within the AfFtn cage, leading to the observed ~12% loading. This loading 
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corresponds to a confinement molarity of ~12 mM (based on a cavity volume of 2.7 x 10-
22 L), the highest reported for a protein-protein host-guest complex to date.202 Our percent 
loading is also similar to that reported for teal fluorescent protein within CCMV capsids.199 
In loading lumazine synthase with GFP(+36), a small population of enlarged capsids was 
observed, suggesting it was more favorable to shift the assembly symmetry of the capsid 
to accommodate greater numbers of GFP(+36), rather than packing GFP(+36) more tightly 
in a smaller volume.118 The AfFtn mutants that maintain greater assembly at low ionic 
strengths (D138K and E65R) had lower GFP(+36) loading than wt or A127R. This 
indicates that encapsulation of GFP(+36) is more favorable starting from AfFtn dimers 
than fully assembled cages. Attempting to increase the loading by adding higher amounts 
of GFP(+36) (1:2 or 1:3 AfFtn:GFP(+36)) was unsuccessful and led to significant protein 
precipitation (Figure 5.9).  
 
Figure 5.9. Excess GFP(+36) per AfFtn 24mer leads to precipitation of both AfFtn and GFP(+36). 
a) Green precipitate seen for 1:2 and 1:3 samples, but not 1:1. b) SDS-PAGE shows precipitate 
contains both AfFtn and GFP(+36).  
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We also repeated the Ni-NTA binding assay for the mutant AfFtn-GFP(+36) 
samples (Figure 5.10). Supporting encapsulation, the majority of GFP(+36) was seen to be 
unbound for all AfFtn-containing samples, with a small amount binding the resin for wt, 
A127R, and D138K. AfFtn features four large (4.5 nm) triangular pores, and it is possible 
that although GFP(+36) was inside AfFtn, the His-tag remained somewhat accessible to 
the resin. It is interesting that E65R has little fluorescence in the elution samples compared 
to the other AfFtn variants. We recently determined that E65R self-assembles in octahedral 
symmetry and lacks the large triangular pores (Chapter 2), which would suggest that once 
encapsulated, the GFP(+36) His-tag is less accessible to the Ni-NTA resin. 
 
Figure 5.10. Ni-NTA assay shows lack of Histag binding for all AfFtn-containing samples compared 
to GFP(+36) alone. 
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To confirm that encapsulation is triggered by the high charge of GFP(+36), we 
repeated native gel and size exclusion experiments with enhanced GFP (eGFP), a non-
supercharged variant with enhanced fluorescence.207 eGFP has an estimated net charge of 
-6.4, based on individual amino acid pKa values. As seen in Figure 5.11, we observed no 
overlapping eGFP-AfFtn bands by native gel, nor did we see AfFtn 24mer overlapping 
with GFP fluorescence by SEC. Thus, the encapsulation observed with GFP(+36) is 
dependent on its high charge.  
 
Figure 5.11. Lack of encapsulation for non-supercharged eGFP. a) Native gel showing lack of 
encapsulation. Fluorescent eGFP bands do not overlap with running position of AfFtn, therefore no 
encapsulation is observed. b) Size exclusion chromatography analysis of AfFtn-eGFP. No 
encapsulation is observed by SEC, as only AfFtn dimer is observed (~17 mL) and eGFP 
fluorescence does not overlap with AfFtn absorbance.  
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In addition, we investigated the effect of [NaCl] on encapsulation using E65R, to 
disentangle any effect of pre-assembled cages versus ionic strength. We mixed E65R and 
GFP(+36) in solutions of increasing [NaCl] and ran them on a native gel, shown in Figure 
5.12. At increasing ionic strengths, the fluorescent band corresponding to encapsulated 
product grows dimmer, suggesting the encapsulation is dependent on electrostatic 
interactions.  
 
Figure 5.12. E65R-GFP(+36) native gel with increasing [NaCl]. At increasing ionic strengths less 
encapsulation is observed, as indicated by dimmer fluorescent band traveling towards the positive 
terminal. 
However, once encapsulated, raising the ionic strength of the solution does not 
appear to completely dissociate the protein complex. After incubating wt AfFtn with 
GFP(+36) 1:1 overnight in no salt buffer (20 mM phos, pH 7.6), the salt concentration was 
increased to 400 mM. The sample was run on a size exclusion column equilibrated in high 
salt buffer (20 mM phos, 800 mM NaCl, pH 7.6), as seen in Figure 5.13. While a free 
GFP(+36) peak was observed, most GFP(+36) fluorescence overlapped with the AfFtn 
24mer peak, indicating the majority remained encapsulated. High salt concentrations 
should stabilize AfFtn cages, and yet also disfavor electrostatic interaction between AfFtn 
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and GFP(+36). At the salt concentration used, cage stabilization must be great enough to 
prevent significant leakage of GFP(+36).  
 
Figure 5.13. SEC of AfFtn-GFP(+36) at high ionic strength. Free GFP(+36) is observed, indicating 
that increasing ionic strength does partially disrupt the assembly. However, the majority remained 
encapsulated, suggesting that once encapsulated, the complex is fairly stable. 
5.3 Conclusions 
 We have demonstrated successful formation of a non-native protein:protein 
host:guest complex using archaeal ferritin and supercharged GFP. The charge of GFP is 
important for encapsulation, as non-supercharged GFP was not encapsulated. We can also 
encapsulate GFP within a mutant AfFtn that does not disassemble, which we have recently 
shown to not encapsulate 6-nm AuNPs, unlike wt (Chapter 2). The cage dynamics perhaps 
allow for encapsulation of the smaller and more flexible GFP(+36). Encapsulating 
supercharged proteins within ferritin could be a useful delivery method, rendering the cargo 
less vulnerable to proteolysis and delivering to specific cells bearing one of several 
receptors with affinity for ferritin (Scara584 or TfR183). The ferritin could also be redirected 
to a target of choice by conjugating antibodies88 or targeting peptides to its surface.89  
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5.4 Experimental Procedures 
Protein expression and purification. AfFtn and mutants were expressed and 
purified as described in Chapter 2. SDS-PAGE confirming purity is shown in Figure 5.14.  
 
Figure 5.14. SDS-PAGE showing pure protein for AfFtn wt, A127R, D138K, and E65R used.  
GFP(+36)-His6 plasmid was purchased from DNA 2.0 (now ATUM), based on the 
sequence published by Lawrence et al.205 Plasmid containing eGFP-His6 (pUCBB-ntH6-
eGFP) was a gift from Claudia Schmidt-dannert (Addgene plasmid #32557).208 Plasmids 
were transformed in E. coli BL21CodonPlus(DE3)-RP cells. Cells were grown at 30 °C 
overnight in LB broth, transferred to 1 L LB, and grown at 37 °C until OD600 ~0.6. 
Induction was done with 1 mM IPTG for 4 h at 37 °C. Cells were harvested by 
centrifugation and stored at -20 °C. Cells were resuspended in lysis buffer (phosphate 
buffered saline with 2 M NaCl) and lysed by treatment with lysozyme (~1 mg/mL final 
concentration) and DNAse with stirring at 4 °C for 30 min, followed by sonication on ice 
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(amplitude of 30, 1 s on, 2 s off, 10 min processing time). Cellular debris were removed by 
centrifugation (16 krpm, 30 min, 4 °C). Initial purification was performed using Ni-NTA 
spin columns, washing three times with lysis buffer containing 20 mM imidazole, followed 
by elution with lysis buffer containing 250 mM imidazole. Green fractions were collected 
and buffer exchanged to PBS. Benzonase nuclease and MgCl2 (2 mM final concentration) 
were added and the solution was incubated at rt for 15 min to further remove nucleic acids. 
Using a HiTrap SP HP column, cation exchange was performed by running a gradient 0-
100% over 25 mL using lysis buffer. The sample was then concentrated and run on a 
HiLoad 16/60 size exclusion column equilibrated with lysis buffer at a flow rate of 0.7 
mL/min. Green fractions were collected and concentrated. Purity was verified by SDS-
PAGE (Figure 5.15) and concentration was determined using extinction coefficients at 488 
nm: 8.33x104 M-1 cm-1 (GFP(+36))209, 5.3x104 M-1 cm-1 (eGFP).210 
 
Figure 5.15. SDS-PAGE showing pure protein for GFP(+36), eGFP used.  
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 AfFtn GFP(+36) complex formation. AfFtn-GFP(+36) complexes were formed by 
mixing AfFtn and GFP(+36) in a 1:1 ratio in no salt buffer (20 mM phos, pH 7.6) at a 
concentration of 0.6 µM and equilibrating overnight at 4 °C.  
 Native gel electrophoresis. Native gels (0.7% agarose) were prepared using 5 mM 
NaCl, 20 mM phos, pH 7.6. Samples were mixed with glycerol (final concentration 16% 
v/v). Gels were run at 100 V for 20 min on ice, covered with foil. Gels were imaged using 
a Typhoon FLA7000 imager using an excitation wavelength of 472 nm and PMT setting 
of 500 V. Following fluorescence imaging, gels were stained with Coomassie Brilliant 
Blue R-250. 
 Analytical size exclusion chromatography. Analytical size exclusion 
chromatography was done on an AKTA FPLC system using a Superdex200 Increase 
10/300 GL column equilibrated with no salt buffer (20 mM phos, pH 7.6). Samples were 
prepared as above, but at a concentration of 6 µM for greater signal. 200 µL of sample was 
injected and A280 was monitored. Sample was eluted at 4 °C using a flow rate of 0.9 
mL/min. Fluorescence of individual fractions was measured using a microplate reader as 
described below. 
 Dynamic light scattering. 100 µL of sample were pipetted into a disposable micro 
cuvette. DLS was performed on a Malvern ZetaSizer Nano ZS with a scattering angle of 
173 ° at a temperature of 25 °C.  
 Fluorescence measurements. For GFP(+36) fluorescence spectrum, a Varian Cary 
Eclipse spectrophotometer was used, exciting at 488 nm and scanning 490-550 nm at 30 
nm/min at 25 °C. For fluorescence analysis of size exclusion fractions and Ni-NTA assay 
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samples, a Tecan M1000 microplate reader was used. 100 µL of sample were pipetted into 
a black 96-well plate. Samples were excited at 488 nm and fluorescence was measured at 
509 nm.  
 Ni-NTA assay. Fractions from SEC analysis containing encapsulation product were 
concentrated using a 10k centricon to a volume of ~100 µL. 100 µL of concentrated sample 
was mixed with 100 µL of Ni-NTA resin that had been pre-washed with no salt buffer (20 
mM phos, pH 7.6). Samples were incubated for an hour at 4 °C on an end-over rocker, 
covered in foil. Post-incubation, samples were centrifuged for 2 min at 13.2 krpm to pellet 
the resin. The supernatant was moved to a clean tube for later analysis (“load”). The resin 
was resuspended in lysis buffer containing 20 mM imidazole, centrifuged, and again the 
supernatant was removed (“wash 1”). This was repeated twice more (“wash 2”, “wash 3”). 
After washing, the resin was resuspended in lysis buffer containing 250 mM imidazole, 
centrifuged, and the supernatant was removed (“elution 1”). Again, this was repeated twice 
more (“elution 2”, “elution 3”). The fluorescence of all supernatant samples was measured 
using a microplate reader as described above.  
 Transmission electron microscopy. Grids were prepared by floating a copper-
coated carbon grid on 5 µL of sample and staining with 2% (w/v) uranyl acetate. Grids 
were imaged on a Tecnai T-12 microscope operating at 120 keV. 
Determination of GFP(+36) loading. 1:1 AfFtn:GFP(+36) samples were purified 
by SEC, and the fraction containing the highest fluorescence intensity was selected for 
loading analysis. The UV-visible spectrum of the sample was measured using an Agilent 
8453 UV-visible spectrometer. A280 and A488 were used to calculate the number of 
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GFP(+36) per AfFtn 24mer. The measured A280 has contributions from both AfFtn and 
GFP(+36), while A488 is only due to GFP(+36). An average ratio of A280/A488 for GFP(+36) 
was determined to be 0.46. This was used to calculate the A280 that can be attributed to 
AfFtn: 𝐴SZA,\]^ FW_ = 𝐴VZZ×0.46 𝐴SZA,a0]3b = 𝐴SZA,cde?fgdh − 𝐴SZA,\]^(FW_) 
The concentration of AfFtn was then calculated using the extinction coefficient above, 
while the concentration of GFP(+36) was calculated based on A488 and the extinction 
coefficient listed above. The loading, [GFP(+36)] / [AfFtn], was then calculated.  
 Geometric analysis of AfFtn pores and GFP(+36). The pores of wt-AfFtn are ~4.5 
nm from base to vertex, forming an approximately equilateral triangle with sides of ~5 nm. 
GFP(+36) can be simplified as a cylinder of length 4 nm and diameter 3 nm. To fit 
GFP(+36) lengthwise through the pore, its diameter must be smaller than the largest circle 
that can be inscribed in an equilateral triangle of side length s: 𝑑 = 𝑠3 
For s = 5 nm, d = 2.9 nm, just smaller than the diameter of an idealized GFP(+36) 
cylinder. To fit GFP(+36) height-wise through the pore, its area if flattened to a rectangle 
must be smaller than 50% of the area of the triangle pore. This results in an area for a 
GFP(+36) rectangle of 12 nm2, while the largest possible rectangle to fit through the pores 
has an area of 11.25 nm2. Thus, GFP(+36) should be slightly too large to be encapsulated 
or escape only via movement through the pores.  
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CHAPTER 6: FUTURE DIRECTIONS AND CONCLUSIONS 
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The work in this thesis has demonstrated the utility of AfFtn for the encapsulation 
of useful cargo such as nanoparticles and proteins. We have tuned the self-assembly 
behaviour of AfFtn via computationally-guided mutagenesis, producing three mutant 
AfFtn with a gradient of assembly stability. One mutant, E65R, is remarkably more stable 
with respect to both temperature and ionic strength compared to wt. This mutant may be 
useful for high temperature templated nanomaterial synthesis or targeted delivery in 
physiological conditions, where wt AfFtn would disassemble. Probing the bio-nano 
interface remains non-trivial, but using our graphene-based microelectrode, we have 
demonstrated that AfFtn maintains its native quaternary structure upon encapsulation of an 
AuNP. This device could find additional use in probing charge transfer in other protein-
nanomaterial systems. We have also developed seeded growth AuNP templating with 
AfFtn and explored the effect of the gold salt chosen and the AfFtn pore size. Our results 
demonstrate the advantage of the unique porous structure of AfFtn in achieving high 
templating efficiency. Finally, we have expanded AfFtn encapsulation beyond 
nanoparticles to protein cargo using supercharged GFP.  
There are many applications that can be realized using the AfFtn-cargo complexes 
developed herein, such as increasing catalytic specificity of NPs by encapsulating them 
within AfFtn, delivering therapeutic proteins using antibody-conjugated AfFtn, and 
templating NP growth. However, potential cargo for encapsulation remains limited by the 
internal diameter of AfFtn. Only cargo smaller than 8 nm in all dimensions can fit within 
the cavity, eliminating many NPs whose exotic shapes or larger sizes give them interesting 
catalytic, therapeutic, or optical properties. Cubic nanoparticles could potentially fit inside 
AfFtn by positioning the corners in the large triangular pores of the assembled protein. 
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Platinum nanocubes have been shown to more effectively catalyse oxygen reduction211 and 
methanol and ethanol electrooxidation212 compared to Pt spheres of comparable size. Gold 
nanorods have significant NIR absorbance and are highly effective photothermal therapy 
agents for cancer treatment,59 but the rod width is typically more than 10 nm, and the length 
is 15-70 nm.213 Irregularly faceted iron oxide nanoparticles with larger sizes (up to 18 nm) 
have greater relaxivity and therefore higher contrast for magnetic resonance imaging.214 
Particles with “spiky” surfaces such as spiky gold nanoshells215 or gold nanostars216 can be 
used for surface enhanced Raman scattering. To encapsulate NPs such as these, more 
extensive engineering of the AfFtn cage is needed.  
To increase the versatility of AfFtn for encapsulation, we aim to prepare AfFtns of 
various sizes, as guided by computation. By inserting additional amino acids into the 
middle of all four helices, we expect to create AfFtn with larger inner and outer diameters 
(Figure 6.1).  
 
Figure 6.1 Computationally designed ferritins with enlarged cavities will be designed by inserting 
additional residues into each helix. Figure from Jose Villegas. 
 
Recent work has shown that the ferritin cage is amenable to size manipulation. 
Mutagenesis studies have led to the formation of non-native ferritin assemblies, with more 
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or less than the canonical 24 subunits. Somewhat counterintuitively, Zhang et al.217 created 
an enlarged 48mer ferritin (17 nm outer diameter) by deleting six amino acids within helix 
D of human H ferritin. This large ferritin was stable only in the solid phase, while a smaller, 
disc-like, 8mer ferritin (10 nm outer diameter) was the stable species in solution. By 
inserting seven amino acids in helix D of human H ferritin, a 16mer ferritin cage was also 
produced.218 These studies show that manipulating the ferritin cage is possible, but not 
always intuitive or predictable. Thus, we plan to carefully redesign helix interfaces to allow 
for insertion of additional amino acids, while also maintaining the important inter-subunit 
contacts that promote self-assembly.  
In addition to engineering AfFtn, NP surface chemistry will need to be optimized 
to encapsulate NPs of different compositions and sizes. As the Appendix demonstrates, 
AfFtn encapsulation is highly dependent on surface ligand, as BSPP and citrate-coated 
AuNPs were preferentially encapsulated compared to AuNPs coated with GSH. Further 
studies are needed to understand the specific ligand properties that enable encapsulation 
and work may be needed to incorporate those properties into a ligand that is compatible 
with a specific NP surface.  
Further development is needed in the encapsulation of supercharged proteins. Our 
results indicate that GFP(+36) can be encapsulated but non-supercharged eGFP cannot. 
We are interested in understanding exactly what features are required to nucleate 
encapsulation; e.g. is a charge of +36 a magic number, or are there other highly charged 
GFPs that can also be encapsulated? Will a –36 GFP be encapsulated, or is the positive 
charge important? Based on what we learn using GFP as a model protein, we are interested 
in encapsulating therapeutically relevant proteins, either by tagging them with a 
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supercharged protein14 or a highly charged amino acid tail,11 or by redesigning the protein 
surface itself to be intrinsically more charged.219 We are also interested in exploring what 
advantages encapsulation within AfFtn might afford a protein, such as enhanced thermal 
stability or protease resistance. In addition, the confined environment of the AfFtn cavity 
could be used to mimic cellular crowding for studies of enzyme behavior.  
In summary, we have shown AfFtn to be a versatile nanocontainer capable of 
encapsulating diverse cargo, including metallic and semiconducting NPs and supercharged 
protein. Our studies demonstrate enhanced control over nanoscale self-assembly, and the 
resulting AfFtn-cargo conjugates could find future application in catalysis (AfFtn-AuNP), 
nanomaterials synthesis (AfFtn-AuNP), targeted drug delivery (AfFtn-supercharged 
therapeutic protein), fundamental enzyme studies (AfFtn-supercharged protein), and 
bioimaging (AfFtn-QD).  
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APPENDIX: FERRITIN ENCAPSULATION OF QUANTUM DOTS 
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A.1 Introduction 
Quantum dots (QDs) are semiconducting nanoparticles with unique optical 
properties that make them highly useful in biological imaging,220 sensing,221 and diagnostic 
applications.222 Due to quantum confinement, QDs have bright, narrow emission in the 
visible range.223 The emission wavelength is dependent on size, with larger particles 
emitting in the red, and smaller particles emitting in the blue to UV. Their quantum yields 
and stability against photobleaching are both superior to most organic dyes, making them 
attractive alternatives for imaging biological samples.135  
In order for QDs to be widely used in biological applications, greater understanding 
of their interactions with biomolecules is needed. A number of studies have examined the 
effects of proteins on QDs, particularly on their optical properties. Surface ligand was 
found to play a significant role in encapsulating CdSe/ZnS QDs within brome mosaic virus 
capsid protein assemblies.7 Only HS-PEG-COOH-coated QDs were encapsulated and 
remained stable in solution, while dihydrolipoic acid, streptavidin-biotin-DNA, and lipid 
micelles were all unsuccessful ligands. Upon encapsulation, the PEG-QDs had a slight 3-
5 nm red shift in emission and the appearance of a broad shoulder, which was attributed to 
coupling between multiple QDs encapsulated in the same capsid. A slight blue shift in QD 
emission was observed for PbS QDs in the presence of HSAF,224 as well as for CdTe QDs 
in the presence of denatured BSA225 and for CdSe QDs with metallothionein metal binding 
domain peptide.226 Proteins can also enhance or quench QD fluorescence intensity. 
CdSe/ZnS QDs in the presence of IgG227 or maltose binding protein228 were reported to 
have increased fluorescence, attributed to fewer surface defects present after protein 
adsorption. CdSe with maltose binding protein-metallothionein fusion229 or 
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metallothionein metal binding domain peptide226 and CdTe with denatured BSA225 were 
also reported to increase in fluorescence intensity. A decrease in fluorescence intensity was 
reported for CdSe/ZnS in the presence of various peptides.230  
 To generalize the encapsulation of AuNPs to NPs of other compositions, we have 
attempted to encapsulate CdSe/ZnS/CdS core/shell/shell QDs. CdSe/ZnS QDs have 
excellent fluorescence properties, while the CdS layer allows greater synthetic control 
tuning overall particle diameter. In this chapter we discuss our work exploring the 
interaction between QDs and AfFtn.  
A.2 Results and Discussion 
 Using the same encapsulation process as had been previously used with AuNPs,51 
we mixed AfFtn with CdSe/ZnS/CdS QDs capped with glutathione (GSH). QD surface 
chemistry is different from that of AuNPs, and initial attempts to stabilize QDs using the 
same ligand that had shown successful encapsulation previously (BSPP) were not 
successful. We therefore used GSH instead, which had previously worked in encapsulating 
10 nm AuNPs using a thermocycling process.50 Ferritin secondary structure was essentially 
unchanged, demonstrating no perturbation to the protein (Figure A.1).  
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Figure A.1. Circular dichroism spectroscopy of thermophilic ferritin and thermophilic ferritin 
quantum dot samples.  
Using steady state fluorescence spectroscopy, we saw a significant decrease in QD 
fluorescence in the presence of AfFtn. This decrease continued over time as shown in 
Figure A.2.  
 
Figure A.2. Steady-state fluorescence data over time showing decrease in QD fluorescence 
intensity after addition of AfFtn, 0-24 h.  
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To determine whether this decrease in fluorescence was specific to AfFtn or a 
phenomenon general to protein adsorption under the encapsulation conditions used, we 
incubated several other proteins with QDs and measured their fluorescence. The proteins 
used were bovine gamma globulin (BGG), bovine serum albumin (BSA), conalbumin 
(con), enhanced green fluorescent protein (eGFP), horse spleen ferritin (HSF), horse spleen 
apoferritin (HSAF), and fibrinogen (fib).  
 
Figure A.3. QD fluorescence in the presence of various proteins. a) Fluorescence of protein QD 
samples measured on microplate reader. b) Fluorescence intensity of protein QD samples divided 
by QD fluorescence intensity. c) Samples illuminated by UV lamp showing changes in fluorescence 
over time for protein QD samples.  
BGG and BSA showed slight decreases in fluorescence intensity, con and eGFP showed 
enhancements in fluorescence (though eGFP has natural fluorescence emission similar in 
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wavelength to that of the QD), and HSF, HSAF, and fib showed significant decreases in 
fluorescence intensity. The fib QD sample had obvious precipitation, leading to decreased 
fluorescence. Fibrinogen is prone to polymerization and likely adsorbed to the QD surface 
and aggregated with neighboring fib-QDs, also decreasing fluorescence. HSF has an iron 
core, and metal ions have been shown to quench QD fluorescence.231 HSAF does not have 
an iron core and should be metal-free, similar to tF. We confirmed the absence of iron in 
AfFtn by ICP-OES; thus, metal ions should not be quenching QD fluorescence. Although 
not obvious by eye, particle destabilization/precipitation could also have contributed to 
quenching. To test this, we centrifuged a QD and an AfFtn QD sample for several minutes 
at high speed (>10k rcf) and measured their UV-vis spectra. As shown in Figure A.4, the 
UV-vis spectra are very similar, indicating that little precipitation occurred. Thus, the 
decrease in QD fluorescence cannot be explained by particle destabilization by AfFtn and 
must be occurring through another mechanism. An increase in surface defects leads to 
decreased QD fluorescence. AfFtn and HSAF could be inducing defects by stripping Cd2+ 
from the QD surface, as ferritins have been shown to bind Cd2+ ions.232  
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Figure A.4. UV-visible spectra of QD and AfFtn QD samples post-centrifugation. The samples look 
nearly identical, demonstrating a lack of precipitation. 
 Based on the changes in QD optical properties, AfFtn was clearly interacting with 
the QDs in some way. We were interested in exploring whether the QDs were encapsulated 
by AfFtn. As shown in Figure A.5a, after incubation for 48 h, size exclusion 
chromatography shows three distinct peaks corresponding to bare QDs, AfFtn 24mer, and 
AfFtn dimer. This indicated that some encapsulation was occurring. By native agarose gel 
(Figure A.5b), we also saw some overlap of QD and AfFtn bands after 48 h, though the 
overlap was not complete. Increasing the concentration of both AfFtn and QD at a 1:1 ratio 
did not improve encapsulation yield, nor did increasing the amount of AfFtn added (Figure 
A.6).  
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Figure A.5. Exploring encapsulation of QDs by AfFtn. a) Size exclusion chromatography shows 
three peaks, corresponding to QD alone, AfFtn 24mer, and AfFtn dimer. b) Native gel 
electrophoresis shows some overlap between AfFtn and QD bands after 48 h, but the overlap is 
incomplete.  
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Figure A.6. Native gels varying encapsulation conditions. a) Native gel showing lack of change in 
encapsulation yield with increasing protein and QD concentration. b) Native gel showing lack of 
increased encapsulation yield with increasing AfFtn:QD.  
In an attempt to improve encapsulation, we used a mutant AfFtn, containing one 
interior-facing cysteine per monomer (AfFtn1iC, E131C mutation). Because sulfur has an 
affinity for QD surfaces, we hypothesized that AfFtn1iC would interact more strongly with 
the QD surface and nucleate encapsulation better than wt. We also used different QD 
ligands, including positively-charged cysteamine (which could interact more favorably 
with the negatively charged interior of AfFtn), and 4-mercapobenzoic acid (4-MBA, which 
has more structural similarity to BSPP). To AfFtn1iC-containing samples, b-
mercaptoethanol (bME) was added to avoid disulfide bond formation, which would link 
two dimers and potentially prevent proper 24mer assembly. Although initial experiments 
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suggested encapsulation for cysteamine-coated QDs (Figure A.7a), it was determined that 
bME was facilitating any movement of the QDs on the gel, and overlap of QD and AfFtn1iC 
bands was coincidental (Figure A.7b). bME has a free thiol that could be interacting with 
the QD surface and giving it greater aqueous stability. To verify that its reducing activity 
was not what was leading to the “encapsulated” band, we used a second reducing agent 
without a free thiol, tris(2-carboxyethyl)phosphine (TCEP). By native gel, we did not see 
any apparent encapsulation for AfFtn1iC samples in the presence of TCEP (Figure A.8).  
 
Figure A.7. Native gels in the presence (+) or absence (–) of 1 mM b-mercaptoethanol. a) Apparent 
encapsulation is seen for AfFtn1ic QD coated with cysteamine in the presence of bME. b) Apparent 
encapsulation for cysteamine-capped QDs is shown to be coincidental, not unique to AfFtn1iC, and 
dependent on bME. 
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Figure A.8. Native gel comparing bME vs TCEP reducing agents and AfFtn vs AfFtn1iC. TCEP-
containing ferritin QD samples did not show overlapping ferritin and QD bands, confirming apparent 
“encapsulation” observed for bME is not due to its reducing capabilities.  
To more definitively rule out GSH as a ligand, we tested encapsulation of AuNPs 
capped with GSH. Native gel showed clearly non-encapsulated AuNP-GSH with our 
gentle, RT encapsulation method (Figure A.9a), so other QD ligands were attempted. We 
attempted to use “BSPP-like” ligands that featured an aromatic ring with charged groups, 
but contained a thiol for conjugation to the QD surface. 4-MBA was used with some 
success, as the protein and QD bands appeared to overlap by native gel (Figure A.9b). 
However, ligand exchange with 4-MBA was only partly successful, as the QD fluorescence 
was significantly diminished post-exchange, and diminished further in the presence of 
AfFtn. 
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Figure A.9. Native gels varying NP ligand. a) Native gel showing lack of encapsulation for AuNP 
capped with glutathione (GSH) (red rectangle), compared to AuNPs capped with bis(p-
sulfonatophenyl)phenylphosphine. b) Native gel showing possible encapsulation for 4-MBA-
capped QDs, though QD fluorescence is significantly diminished by this ligand. 
A.3 Conclusions 
 The presence of QDs does not perturb AfFtn structure, though AfFtn does appear 
to partially quench QD fluorescence. While complete encapsulation is not observed, some 
interaction between the QDs and AfFtn is occurring, with changes seen in native gel 
running position, QD fluorescence, and the appearance of AfFtn 24mer by FPLC. Surface 
ligand has a significant effect on NP interaction with AfFtn as seen by native gel, with 
AuNP-BSPP showing complete encapsulation and AuNP-GSH showing none. Further 
work remains to find a ligand that is compatible both with QD surface chemistry and the 
AfFtn interior.  
A.4 Experimental Procedures 
AfFtn Expression and Purification. AfFtn was expressed in 
BL21(DE3)CodonPlus-RP cells cultured in terrific broth medium growing at 37 °C, until 
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OD ~ 0.6. The bacteria were induced with 1 mM IPTG for 4 h at 37 °C. Cells were lysed 
by sonication and cellular debris was pelleted by centrifuging at 6 krpm, 4 °C, 30 min. The 
supernatant was heat shocked for 10 min at 80 °C and centrifuged again, 9 krpm, 4 °C, 90 
min. The supernatant was applied to an anion exchange column and fractions containing 
tF were collected, concentrated, and buffer exchanged into assembly buffer (2 M NaCl, 2 
mM EDTA, 20 mM phos, pH 7.6) and incubated overnight at 4 °C. The sample was then 
concentrated and injected onto a size exclusion Superdex200 10/300 GL column 
equilibrated with high salt buffer (800 mM NaCl, 20 mM phos, pH 7.6). Fractions 
containing 24mer were combined and concentrated. Protein purity was assessed using 
SDS-PAGE and concentration was determined using the Bradford assay.  
QD Synthesis and Characterization. QDs were synthesized as previously 
published233 and were generously provided by Dr. Matteo Cargnello. Briefly, oleic acid-
protected CdSe QDs were prepared using cadmium oleate (0.5 M in 1-octadecene, 1 mmol) 
and elemental selenium (0.5 mmol) as precursors. After reaction at 240 °C for 30 minutes, 
ZnEt2 and (TMS)2S (1 mmol each) dissolved in 6 mL trioctylphosphine were injected using 
a syringe pump at 0.1 mL min−1. The outer CdS shell was added using Cd(olac)2 (0.5 M in 
1-octadecene) and (TMS)2S (2 mmol each), dissolved into 12 mL of trioctylphosphine and 
injected at 0.1 mL min−1. The mixture was cooled to RT and QDs isolated and purified by 
centrifugation using isopropanol and methanol as anti-solvents. For ligand exchange into 
aqueous solutions, isopropanol and ethanol were used to precipitate 1 mL of QD solution. 
The solution was centrifuged (8 krcf, 5 min) and resuspended in chloroform. A fresh 
solution of aqueous ligand (containing 100 mg KOH) was added to the resuspended QDs 
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and stirred at RT for 1 h. The now aqueous QDs were washed with acetone and water three 
times and finally stored in water. QDs were characterized by TEM for particle size and 
UV-vis spectroscopy to monitor ligand effect on QD optical properties (Figure A.10).  
 
Figure A.10. QD characterization. a) TEM micrograph showing monodisperse particles of 6 nm 
average diameter. b) Fluorescence spectrum post-ligand exchange to GSH showing emission peak 
at 590 nm.  
AfFtn QD Encapsulation. AfFtn and QDs were mixed at a ratio of 1:1 AfFtn 
24mer:QD at a concentration of 1 µM, in low salt buffer (20 mM phos, 20 mM NaCl, pH 
7.6), covered in foil, and incubated at RT on a gel rocker for 48 h.  
AfFtn QD Characterization. CD data were obtained using an Aviv 410 CD 
spectrometer (Aviv Biomedical; Lakewood, NJ) with a 1 mm quartz cuvette (Hellma 
USA). Samples were 0.25 µM in low salt buffer, scanned 190-260 nm, with a 15 s 
averaging time, at T = 25 °C. Native agarose gels (0.7%) were run at 100 V for 20 min at 
room temperature, with 5 mM NaCl, 20 mM phos (pH 7.6) as the running buffer. Gels 
were imaged using a Typhoon FLA7000 Imager exciting at 473 nm to image QD bands 
and staining with Coomassie dye to visualize AfFtn. Steady-state fluorescence spectra were 
	150 
	
collected on a Varian Cary Eclipse fluorescence spectrophotometer (Cary Eclipse software, 
2003) using a 100 µL quartz cuvette (Starna Cells). Samples were prepared at 0.6 µM. 
Samples were excited at 350 nm, scanned 500-700 nm at 30 nm/min, with a PMT voltage 
of 500 V, at 20 °C. Microplate fluorescence measurements were done on an Infinite M1000 
microplate reader (Tecan) using top detection, exciting at 350 nm, scanning 550-650 nm. 
Analytical size exclusion chromatography was done on a Superdex200 10/300 GL column, 
equilibrated with low salt buffer (20 mM NaCl, 20 mM phos, pH 7.6). Samples were 
injected after 48 h incubation at rt with gentle agitation, at a volume of 100 µL. UV-visible 
absorbance spectra were measured over the range 200–1100 nm at 25 °C using an Agilent 
8453 UV-visible spectrometer.  
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